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ABSTRACT OF THE DISSERTATION
THE ROLE OF REDOX SIGNALING IN THE MOLECULAR MECHANISM OF
TAMOXIFEN RESISTANCE IN BREAST CANCER.
by
Nana Aisha Garba
Florida International University, 2011
Miami, Florida
Professor Deodutta Roy, Major Professor
The emergence of tamoxifen or aromatase inhibitor resistance is a major problem in the
treatment of breast cancer. The molecular signaling mechanism of antiestrogen resistance
is not clear. Understanding the mechanisms by which resistance to these agents arise
could have major clinical implications for preventing or circumventing it. Therefore, in
this dissertation we have investigated the molecular mechanisms underlying antiestrogen
resistance by studying the contributions of reactive oxygen species (ROS)-induced redox
signaling pathways in antiestrogen resistant breast cancer cells. Our hypothesis is that the
conversion of breast tumors to a tamoxifen-resistant phenotype is associated with a
progressive shift towards a pro-oxidant environment of cells as a result of oxidative
stress. The hypothesis of this dissertation was tested in an in vitro 2-D cell culture model
employing state of the art biochemical and molecular techniques, including gene
overexpression, immunoprecipitation, Western blotting, confocal imaging, ChIP, RealTime RT-PCR, and anchorage-independent cell growth assays.

We observed that

tamoxifen (TAM) acts like both an oxidant and an antioxidant. Exposure of tamoxifen
resistant LCC2 cell to TAM or 17 beta-estradiol (E2) induced the formation of reactive

v

oxidant species (ROS). The formation of E2-induced ROS was inhibited by co-treatment
with TAM, similar to cells pretreated with antioxidants. In LCC2 cells, treatments with
either E2 or TAM were capable of inducing cell proliferation which was then inhibited by
biological and chemical antioxidants. Exposure of LCC2 cells to tamoxifen resulted in a
decrease in p27 expression. The LCC2 cells exposed to TAM showed an increase in p27
phosphorylation on T157 and T187. Conversely, antioxidant treatment showed an
increase in p27 expression and a decrease in p27 phosphorylation on T157 and T187 in
TAM exposed cells which were similar to the effects of Fulvestrant. In line with previous
studies, we showed an increase in the binding of cyclin E–Cdk2 and in the level of p27 in
TAM exposed cells that overexpressed biological antioxidants. Together these findings
highly suggest that lowering the oxidant state of antiestrogen resistant LCC2 cells,
increases LCC2 susceptibility to tamoxifen via the cyclin dependent kinase inhibitor p27.
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I.

INTRODUCTION

The fact that a majority of breast cancer express estrogen receptor alpha (ERα), has
informed the use of antiestrogens as one of the drugs of choice for ER+ breast cancers.
Anti-estrogens which act by inhibiting the function of ERs include tamoxifen, raloxifen
and fulvestrant1. Tamoxifen is the most commonly used treatment for patients with ER+
breast cancer and its use as a breast cancer preventative agent and an adjuvant therapy in
early cancer has been shown to improve the overall survival2, 3. Furthermore, the
extensive use of tamoxifen has made a significant contribution to the reduction in breast
cancer mortality seen over the last two decades.

However, in spite of the obvious benefits of tamoxifen in breast cancer treatment, almost
all patients with metastatic breast disease and as many as 40% of patients receiving
adjuvant tamoxifen eventually develop resistance and die from their disease1. Hence the
issue of tamoxifen resistance has been a major setback in an otherwise successful
treatment of ER+ breast cancer.

Though a number of pathways have been proposed and explored, to date there has been
no clear mechanism implicated in the development of anti-estrogen resistance. A hitherto
unexplored mechanism involves the role of reactive oxygen species (ROS) in the
mechanism of tamoxifen resistance. (ROS) comprise of either partially reduced
metabolites of oxygen such as superoxide anions (O2− •); peroxyl radicals (LOO.) and
hydroxyl radicals (OH·) or non-radical molecules like hydrogen peroxide (H2O2) and
singlet oxygen (1O2); which have a higher reactivity than molecular oxygen4. They are
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products of cellular metabolism which have been shown to induce oxidative stress. An
excessive and/or sustained increase in ROS production has been implicated in the
pathogenesis of cancer5, 6. Furthermore, ROS induced oxidative stress has been shown to
initiate a number of different responses including cell proliferation and transformation;
alteration of intracellular redox state and the oxidative modification of certain signaling
proteins resulting in the post translational modification7 of their downstream targets.
Interestingly, like estrogen, tamoxifen has been shown to induce ROS formation, making
it probable that tamoxifen induced ROS generated as a result of prolong tamoxifen
treatment of breast cancer patients may play a vital role in the development of tamoxifen
resistance.

As protection against oxidative stress, cells have several enzymic and nonenzymic
antioxidants or reductants that maintain the intracellular redox environment in a
principally reduced state. Typically the enzyme superoxide dismutase (SOD) catalyses
the conversion of O2− to H2O2, and then the H2O2 generated is degraded to H2O by
several cellular enzymes, usually Catalase or glutathione peroxidase coupled with
glutathione reductase8, 9. It is however interesting to note that in most cancer tissue the
levels/ activity of manganese superoxide dismutase and Catalase have been found to be
almost always low. Making a case for the existance of a pro-oxidative environment in
cancer cells that may result in an oxidative stress surge and redox signaling culminating
in uninhibited cell proliferation.
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Hypothesis and Specific Aims
We hypothesize that the conversion of breast tumors to a tamoxifen-resistant phenotype
is associated with a progressive shift towards a pro-oxidant environment, as a result of
chronic oxidative stress. We further postulate that an increase in reactive oxygen species
(ROS) levels promotes either the loss of p27 inhibitory function or NRF-1 activation
through the inactivation of protein tyrosine phosphates (PTPs) with consequent changes
in p27 and/or NRF-1 phosphorylation.

To test this hypothesis, we explored the following Specific Aims:
Aim 1. To investigate whether anti-estrogens prevent estrogen-mediated progression of
cell cycle by counteracting estrogen-induced ROS signaling. To further investigate if
reducing the oxidative environment of anti-estrogen-resistant breast cancer cells restores
the anti-proliferative action of tamoxifen.

Aim 2. To determine mechanisms by which a pro-oxidative state may promote p27
inactivation, and thus cell cycle progression.

Aim 3. To determine mechanisms whereby a pro-oxidative state may promote oxidation
of protein tyrosine phosphatase PTEN, NRF-1 activation and cell cycle progression.

Findings of this study will elucidate the roles of the cellular redox state, redox signaling
pathways, PTPs and p27 in anti-estrogen resistance, and may lead to new therapeutic
strategies to delay or even prevent this important clinical problem. This is a new line of
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research that may lay the groundwork for clinical trials of anti-estrogens plus antioxidantbased drugs for the prevention and treatment of estrogen-dependent breast cancer.

II.

LITERATURE REVIEW:

THE ROLE OF REDOX SIGNALING IN THE MOLECULAR MECHANISM OF
TAMOXIFEN REISTANCE IN BREAST CANCER TREATMENT

Abstract
Anti-estrogens are one of the classes of drugs used to treat ER+ breast cancer. Since their
discovery they have been the drugs of choice in breast cancer treatment; prevention and
adjuvant therapy for early breast cancer cases. Although anti-estrogens have been
beneficial to a large number of patients, unfortunately about 40% of breast cancer
patients and a majority of patients with metastatic breast disease who were initially
responsive to the drugs will relapse and die of the disease. In spite of the current breakthrough in our knowledge of the molecular mechanisms that contribute to resistance, antiestrogen resistance remains a major setback in the treatment of ER+ breast cancer. In this
review we examine the previously unexplored role of reactive oxygen species (ROS) and
redox signaling in the molecular mechanism that contribute to breast cancer resistance to
anti-estrogens.

Introduction
In the majority of invasive breast tumors estrogen receptor alpha (ERα) is often upregulated while ERβ is down-regulated. This finding is the basis for the therapeutic use of
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antiestrogens, which are drugs that disrupt the actions of estrogen and ERα1. The types of
antiestrogens used include those that inhibit the function of estrogen receptors such as
tamoxifen, raloxifene, and ICI 182,780 (fulvestrant), or the aromatase inhibitors such as
letrozole and exemestane which block the conversion of androgens into biologically
active estrogens.Over the years the successful use of these groups of drugs has been
plagued by the emergence of drug resistance, which to date remains a major problem in
the treatment of breast cancer.

Herein, we reviewed the role of estrogen and its receptors in the development of breast
cancer and the function of tamoxifen as an antiestrogen. We also examined the role of
reactive oxygen species (ROS) as signaling molecules and how they may induce
antiestrogen resistance by altering the post-translational status of certain signaling
proteins which are key players in the cell cycle.

An overview of Estrogen and ER action
The human breast like that of other mammalian species contains both epithelial and
mesenchymal components and a vast majority of malignant tumors are epithelial in
origin1.

In normal breast cells, estrogen and estrogen receptors are critical regulators which
enable the mammary epithelial cells to undergo proliferation, differentiation, apoptosis
and remodeling in the course of the mammalian reproductive lifespan1, 10, 11.
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Studies have shown that estrogens initiate different growth responses in tissues
depending on the cell type, the dose and the timing of exposure 12. Moreover, it is now
generally accepted that, in addition to its role in the promotion of breast tumors, estrogen
also supports the growth of pre-neoplastic and malignant cells through ER-mediated
signaling pathways13.

The conventional model of estrogen action is based on its binding to ERα/β receptors,
which initiates transcription either directly by binding to estrogen response elements
(EREs) in the promoter region of target genes or indirectly through the phosphorylation
of signaling proteins involved in cell cycle progression 14, 15. Overall, estrogen regulates
the expression of many genes important for normal cell physiology and growth of some
breast tumors 16.

Both experimental and epidemiologic data suggest that estrogen plays a significant role in
carcinogenesis17 , 15. In malignant breast tissue, the action of estrogen and its steroid
receptors is dysregulated, resulting in a shift to proliferation without differentiation and
apoptosis, and an increase in the percentage of epithelial cells expressing ERα.
Additionally, cell proliferation makes a change from paracrine to autocrine growth 18 . It
is noteworthy that the risk of breast cancer is, in part, due to the duration of proliferation
without differentiation.
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Estrogen Receptors (ER)
Normal human breast cells contain two types of E2 receptors, namely ERα and ERβ,
which are the products of separate genes. ERα is expressed in 15 – 30% of the luminal
epithelial cells (so called estrogen receptor positive cells) while ERβ is more widely
expressed in the mammary tissue1;19, 20. ERβ is co-expressed with ERα in the luminal
epithelial cells, but can also be found in the myoepithelial cells as well as in the stromal
cells. In the normal luminal epithelial breast cells, estrogen-dependent proliferation
occurs in a paracrine manner with ERα containing cells producing growth factors that
induce proliferation in adjacent estrogen-negative cells.

Deletion of both ERα and ERβ genes has revealed the significance of E2 for normal
female sex organ development and function 20;21. Both in vivo and in vitro studies in
mammals have postulated that E2 plays a considerable role in the maintenance of bone22 ,
vascular integrity, and brain function. Estrogen has also been shown to be a significant
growth and survival factor for human breast cancer cells 23, 24. ERs act principally as
nuclear transcription factors, an event that is enhanced by ligand binding. Though a
separate pool of receptors for E2 in the cytoplasm and plasma membrane have been
identified, the mechanisms of action and cellular functions of these proteins are just
beginning to be unraveled.

Estrogen Receptors: Nuclear/genomic pathway
The ‘genomic action’ of E2 occurs after a time-lag of at least 2 h following E2
stimulation. This action accounts for some hormone functions in physiological and
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pathological situations 25, 26.The nuclear ER contains domains lettered A through F, with
activation function (AF)-1 (ligand independent) and AF-2 (ligand dependent) facilitating
the transactivation of target genes27.

In the so called ligand dependent pathway, ER functions in the nucleus as a
transcriptional regulator of specific genes. The receptor protein has a ligand-binding
domain (AF-2), several transcription activation domains, and a DNA-binding domain that
interacts with specific regions in the promoter of target genes, including sites known as
estrogen-responsive elements (ERE) 28-30. The binding of estrogen to ER induces
phosphorylation of the receptor, alters its conformation, and triggers receptor
dimerization.

The ER protein in the nucleus can also modify transcription of genes through proteinprotein interactions. In this way, ER can function much like a coactivator protein itself by
binding to other transcription factors and recruiting acetyltransferases to complexes
bound to activator protein or SP-1 sites on DNA31. This is how estrogen helps to regulate
genes encoding proteins such as cyclin D1, insulin-like growth factor I receptor (IGF-IR),
and collagenase. ER has also been to be able to decrease the expression of many genes32.

In the ligand-independent pathway, the estrogen receptor translocates to the nuclear
membrane from the cytosol and can activate transcription in a ligand-independent
fashion33. These transcriptional activities of ER have been called its classical or genomic
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activity. From a functional perspective, a more appropriate term is nuclear-initiated
steroid signaling.

Membrane-initiated Estrogen signaling
In contrast to the nuclear effects, ER functions that can occur very rapidly in the cell
before new gene transcription takes place have been identified. This membrane-initiated
steroid signaling could occur outside the nucleus or even in the cell membrane 34. A
number of studies based on endothelial and breast cancer cells have been able to show
that a small group of ER is positioned outside the nucleus in the cytoplasm or bound to
the plasma membrane35, 36 37, 38. It is thought that the presence of a membrane-bound ER
may explain the previously identified short-term effects of estrogen (occurring within
minutes) in cultured cells39, 40. Further investigations have indicated that E2 rapidly
activates signaling, such as calcium flux,41 phospholipase C activation 42 and inositol
trisphosphate (IP3) generation. Most studies suggest that these actions necessitates E2
binding to ERs. In neural cells, ERs can activate protein kinase C and protein kinase A.
They can also uncouple opioidergic and gabanergic receptors from their effector
signaling molecules40. These signaling events are likely to be as a result of E2 activation
of G proteins. Therefore, ERs appear to be part of the large family of G-protein-coupled
receptors (GPCR). After several G proteins are activated, E2-ER can then trigger
signaling cascades that terminate in a cell biological function.
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Antiestrogen (Tamoxifen) Action
Tamoxifen belongs to a class of therapeutic agents called the selective estrogen receptor
modulators (SERMs). These drug function as estrogen receptor (ER) antagonists in breast
tissue and as ER agonists in the endometrium, heart and bones43. 4-hydroxy-tamoxifen is
an active metabolite of tamoxifen, which has been shown to compete for binding with
natural estrogen to the ERα with high affinity44, 45.

Subsequent to the antagonist binding to ERα, a different 3-dimensional structure is
elicited in the receptor, which renders it unable to enhance specific gene expression.
Therefore antiestrogens interrupt the estrogen-induced signals, which can result in the
inhibition of cell proliferation, tumor growth arrest, and induction of apoptosis46; 47, 48.

In vitro tamoxifen has been shown to induce G1 phase cell cycle arrest in ER-positive
breast cancer cells exposed to estrogens. 1; 49, 50;51 creating an avenue by which genes that
control cell cycle progression could significantly impact drug sensitivity and resistance.
Furthermore, tamoxifen has the capacity to indirectly decrease levels of cyclin D152 .

In vivo, tamoxifen inhibits estrogen-stimulated growth of MCF7 xenografts in mice and
prevents development of breast cancer in the NMU and DMBA rodent models53, 54.
Similar to estrogens, tamoxifen increases the expression of IGF-I and vascular
endothelial cell growth factor in the uterus.55, 56 In clinical specimens acquired
sequentially from patients with breast cancer, administration of tamoxifen has been

10

shown to reduce proliferation, upregulate ER expression, downregulate TGFα and induce
stromal TGFβ157-60.

Other classes of therapeutic agents are the selective estrogen receptor down regulators
(SERDs) and aromatase inhibitors (AI). SERDs include ICI182780 (Fulvestrant), which
is a pure estrogen antagonist with a 100-fold greater affinity for ER than tamoxifen. By
binding ER it inhibits receptor dimerization and abrogates estrogen signaling17.
Aromatase inhibitors are a second line therapy for post–menopausal patients who have
progressed after tamoxifen treatment. They act by inhibiting the action of aromatase
which is an enzyme necessary for the conversion of androgens to estrogens.
It is interesting to note that the majority of tumors that develop resistance over time
continue to express ERα10;11 . Furthermore, many of the tamoxifen-resistant tumors still
respond to fulvestrant and AIs, indicating that estrogen remains an important regulator of
tumor growth under these circumstances10. These data provide support for the idea that
endocrine targeted therapies can lead to the activation of novel signaling pathways that
evade the effects of antiestrogens.

Redox signaling
Redox Signaling is process whereby activated or free radicals and reactive oxygen
species act as messengers in the biological system. It involves a vital and continuous
process by which human cells communicate with each other and carry out essential
functions in the body. Redox signaling often entails oxidation-reduction specific
reactions.
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Unlike signal transduction which usually involves both reversible and irreversible
modifications of second messengers and proteins, redox signaling entails at least one
reversible reaction involving the oxidation of a signaling molecule by a reactive species.
It may therefore be inferred that the reaction of reactive oxygen or nitrogen species with
their target is akin to the on-off signaling associated with phosphorylation than it is to the
nonenzymatic lipid peroxidation.

According to Forman et al., 61 redox signaling occurs when at least one step in a signaling
pathway involves one of its components being specifically modified by a reactive species
through a reaction that is chemically reversible under physiological conditionsand/or
enzymatically catalyzed.

Signaling molecules: Reactive Oxygen or Nitrogen species
Both reactive oxygen and nitrogen species are known redox signaling molecules.
Reactive nitrogen species (RNS) are molecules having nitrogen atoms, which because of
their chemistry, are regarded as being highly reactive towards other cellular components.
These molecules may or may not have unpaired electrons. Examples of RNS include
radicals like Nitric Oxide (NO.), Nitrogen dioxide (NO2.) and non rasicals like
Peroxynitrite (ONOO-). On the other hand, Reactive oxygen species (ROS) constitutes
either partially reduced metabolites of oxygen such as superoxide anions (O2− •); peroxyl
radicals (LOO.) and hydroxyl radicals (OH·) or non-radical molecules like hydrogen
peroxide (H2O2) and singlet oxygen (1O2); which have a higher reactivity than molecular
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oxygen. ROS are by-products of normal cellular aerobic metabolism and the exposure of
cells to certain forms of stress results in an increase in the level of ROS generated. It is
note worthy that high level of reactive oxygen species are injurious to cells because of
their tendency to react with a number of intracellular targets, such as proteins, lipids, and
DNA. Conversely, quite a number of studies have shown that reactive oxygen species
posses a variety of physiologic functions at low concentrations. These functions include
but are not limited to: the regulation of gene transcription 62, signal transduction
pathways 63-66 mitosis 67, apoptosis 67, 68, and senescence 68, 69. Additionally, it has been
shown that the stimulated production of oxidants plays a vital role in the mitogenic
response to many growth factors 63, 66, 70 For example, ROS have been shown to play a
vital role in cell growth mediated by 17β-estradiol (E2),71 peptide growth factors and
cytokines including PDGF 66, vascular endothelial growth factor, insulin, and tumor
necrosis factor72.

Regarding their role as signaling molecules, some reactive oxygen species such as H2O2 ,
are considered key signaling molecules, while others appear to be particularly harmful to
living systems73. In higher organisms, low to moderate concentrations of NO and ROS
are utilized as signaling molecules for other normal cellular functions like: their
physiological roles in the cellular responses to oxygenation, as in the defense against
infectious agents; the initiation of a number of cellular signaling systems and the
induction of a mitogenic response 72, 74, 75. Furthermore, exposure to a variety of nonphysiologically significant concentrations of ROS or RNS that induce oxidative stress but
do not kill cells can stimulate responses such as repair, adaptation, or transformation76.
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On the other hand, excessive and/or sustained increase in ROS production has been
implicated in the pathogenesis of cancer 5, 5, 6. as well as other metabolic diseases like
diabetes mellitus72. Tumor cells have been shown to have a high and persistent oxidative
stress 77. Free radicals are involved in initiation 78 as well as promotion/ progression
stages of tumorigenesis 79, 80 while inhibitors and scavengers of ROS inhibit these stages
of tumor development 81, 82.

Based on work done on the release of ROS by non phagocytic cells, and on cells where
ROS have no apparent role, ROS has been shown to be key signaling molecules, even
though their exact mode of action was relatively unknown. Currently several studies have
shown the ability of ROS to induce necrosis at high concentrations, as well as its role in
the induction/inhibition of cell proliferation, and in the activation/inhibition of
apoptosis83, 84.

Sources of reactive oxygen species
ROS (usually O2− •) can be generated intracellularly by a number of enzymes including
NADPH oxidase which upon stimulation undergo a respiratory burst, with the release of
superoxide into the phagosome85, 86 the endoplasmic reticulum which is another site of
electron transport, where O2− • is generated by the leakage of electrons from NADPH
cytochrome P450 reductase87 cytosolic oxidases; xanthine oxidase and lipoxygenase, and
the mitochondrion. In the mitochondria, reactive oxygen species like O2− • and H2O2 are
often generated as by-products of electron transfer reactions that occur during the
operation of the mitochondrial electron transport chain. ROS is generated in the
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mitochondrial electron transport chain as a result of “leakage”88 of electrons from
electron carriers that are passed directly to oxygen, reducing it to O2 −. An evidence of
this mode of ROS generation is substantiated by the fact that the mitochondria contain
their own superoxide dismutase, an inducible Mn2+-dependent enzyme 89, for rapid
elimination of such reactive species and from a study by Felty et al.90 which identified the
mitochondrion as a major source of estrogen-induced ROS in breast cancer cells.

ROS is also generated by the metabolism of arachidonic acid by the enzymes
cyclooxygenases and lipoxygenases. Prostaglandin H synthase is a major enzyme in the
biosynthesis of prostaglandins, prostacyclins, and thromboxanes. Prostaglandin H
synthase possesses both cyclooxygenase and hydroperoxidase activity91, hence it has the
capacity to generate ROS as oxidizing equivalents via side-chain reactions that are
dependent upon the presence of a suitable reducing substrate such as NADH or NADPH .

Nitric oxide (NO ) is generated from the conversion of the amino acid l-arginine to lcitrulline by NOS. NO is an important reactive species containing both nitrogen and
oxygen. Production of NO by neutrophils is well documented, but there are important
interspecies differences in the amount of NO produced: rodent neutrophils produce
substantially more ROS than human cells 92;93.

17β-estradiol (Estrogen) induces ROS formation
Presently there are several postulates that E2-induced mitochondrial ROS is involved in
the growth and proliferation of estrogen-dependent cells. Felty et al.94 reported that
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physiological concentrations of E2 stimulate a rapid generation of intracellular ROS and
intracellular ROS have been implicated in the promotion of rapid cell cycle activity in
neoplastic cells.

One attribute of rapidly dividing cancer cells is their ability to generate significant
quantities of intracellular ROS. Studies have shown that estrogen-induced stimulation of
both MCF-7 and macrophage cells is partly due to the effect of ROS95, 96. In an
unpublished data by Singh et al., it was observed that scavengers of ROS such as Nacetylcysteine, ebselen, and catalase inhibited the estrogen-induced growth of MCF-7
cells, lending credence to the proposed role of ROS as an autocrine growth signal in
estrogen-induced cell proliferation97. Based on a study by Taylor et al.98, which
established that oxidative stress modifies mitochondrial matrix protein thiols, Felty and
Roy 97 extrapolated that an estrogen-mediated cell growth through mitochondrialgenerated ROS signaling molecules may exist. This was based on the reasoning that since
exposure to estrogen can generate mitochondrial ROS, the oxidation of thiols in response
to estrogen converts the oxidative stress to a change in protein function that is involved in
cell growth.

In a study of E2-induced ROS generation in MCF-7 and other cells, the measurable
events occurred earlier than a regular ER-mediated genomic action. This lead to the belief
that E2-stimulated ROS production does not depend solely on the presence of the ER in
breast cancer cells. Further more, because the ER-negative cell line MDA-MB 468 upon
E2 stimulation was able to produce ROS equal in amount to that of ER-positive cell lines

16

such as MCF7, T47D, and ZR75, it was inferred that, ROS formation upon E2 exposure
might explain oxidative damage to hormone-dependent tumors and ensuing genetic
alterations 99, 100. A few studies have also revealed that E2-induced production of ROS
also provides systematic support for the generation of mutations by physiological
concentrations of estrogens101, 102.

In 2006, Felty103 showed that estrogen exposure of human umblical vein and endothelial
cells (HUVECs) stimulated a rapid production of intracellular ROS that is involved in
signaling endothelial cell growth. He also showed that the early E2 signaling did not
require ER-mediated genomic signaling, because E2-induced growth could be inhibited
by antioxidants. The functional outcomes of E2-induced ROS formation include an
increase in phosphorylation of the signaling proteins C-jun and CREB, as well as the
activation of the binding of three oxidant-sensitive transcription factors AP-1, CREB, and
possibly nuclear respiratory factor 1(NRF-1)90.

Additional findings by Felty et al. suggest that E2-induced mitochondrial ROS modulate
G1 to S transition and some of the early G1 genes through a nongenomic, ERindependent signaling pathway resulting in the conclusion that estrogen-induced
mitochondrial oxidants control the early stage of cell cycle progression, which could
provides the basis for the discovery of novel antioxidant-based drugs or antioxidant gene
therapies for the prevention and treatment of estrogen-dependent breast cancer 104.
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Tamoxifen induces ROS formation
In addition to its role in inhibiting the growth of ER-positive breast cancer cells through
its antiestrogenic properties 105, tamoxifen also appears to have effects on many ERnegative cancer cells106-109. Though the mechanism of this action is not known, as in the
case of E2, studies have found the effect of tamoxifen on ER-negative cells to be related
to its non-genomic actions.

It has been reported that tamoxifen-induced apoptosis in ER-negative HepG2 human
hepatoma cells is mediated by increased intracellular Ca2+ 110 and a consequent
generation of ROS 111. In the study by Lee et al.111, ROS appeared to be a downstream
signal of elevated intracellular Ca2+ , given that their generation was temporally preceded
by elevation of intracellular Ca2+ within a time frame, and completely inhibited by
intracellular and extracellular Ca2+ chelating agents. Another study by Kallio et al 112
showed that at high doses tamoxifen was able to induce apoptosis through the production
of ROS in MCF 7 cells.

Tamoxifen-induced ROS generation has been shown to be produced by membrane bound
NADPH oxidase113 and not to the activation of enzymes like microsomal enzyme,
cytochrome P-450, and numerous catalytic cytosolic enzymes, including cyclooxygenase.
The is because ROS production was not altered by treatment with specific inhibitors of
these enzymes111. NADPH oxidase has also been functionally active in nonphagocytic
cells, including endothelial cells114, vascular smooth muscle cells,115 neuroepithelial
bodies of the lung 116 and type I cells of the carotid body117. The components of the
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NADPH oxidase have been expressed in HepG2 cells118, 119 and the enzyme appears to be
a major source of ROS produced by hypoxia118. Lee et al 111. also reported that the
NADPH oxidase acts as a major site of the tamoxifen-induced ROS production.

Tamoxifen as a scavenger of ROS
Several studies including a study by Kuo et al 120 have shown that 4-OHT (an active
metabolite of Tamoxifen) possesses a potent superoxide anion radical-scavenging
tendency. The presence of phenolic groups in tamoxifen, (much like raloxifen and E2)
confers its antioxidant action chiefly because phenolic structures have the capacity to
bind iron, in addition to reducing peroxyl or alkoxyl radicals 121. In addition, several
studies 239;122, 123;124;125 including one by Arteaga et al.126, 127 have shown that tamoxifen is
a scavenger of ROS.

The role of ROS in oxidative stress and redox signaling
The harmful effect of free reactive oxygen and/or nitrogen species resulting in possible
biological damage is called oxidative stress and nitrosative stress respectively128-130.
Oxidative and nitrosative stress occur in biological systems following an over production
of ROS/RNS as well as an accompanying insufficiency of enzymatic and non-enzymatic
antioxidants. Simply put, oxidative stress refers to a disturbance in the balance between
pro-oxidant/antioxidant reactions in living organisms. As mentioned previously in this
review, excess ROS can damage cellular lipids, proteins, or DNA by hindering their
natural function. Hence it comes as no surprise that oxidative stress has been implicated
in a number of human diseases as well as in the ageing process131.
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Redox regulation, on the other hand, is a very important system responsible for the fairly
fragile balance between the beneficial and the harmful effects of ROS/RNS. According to
Droge 72, the redox regulation process protects living organisms from a variety of
oxidative stresses and maintains the so-called “redox homeostasis” by controlling the
redox status in the living system132.

Redox balance, which is the ratio between oxidizing and reducing species within the cell,
plays a significant role in the regulation of signaling pathways, including kinase and
phosphatase activity as well as gene expression through regulation of the function of
transcription factors 7, 133, 134, 134

As protection against oxidative radical stress, cells have several enzymic and nonenzymic
anti-oxidants or reductants that maintain the intracellular redox environment in an
especially reduced state. Typically the enzyme superoxide dismutase (SOD) catalyses the
conversion of O2− to H2O2, and then the H2O2 generated is degraded to H2O by several
cellular enzymes, usually catalase or glutathione peroxidase coupled with glutathione
reductase 135, 136 (see eqn 1).
O2 + e− → O2-•

SOD

H2O2

Catalase

GSH peroxidase

H2O (eqn1)

Other relevant scavengers include thioredoxin coupled with thioredoxin reductase, and
glutaredoxin, which uses GSH as a substrate. GSH plays a central role in maintaining
redox homeostasis.The GSH to oxidized glutathione ratio (2GSH/GSSG) provides an
estimate of cellular redox buffering ability137. Forman et al.138 have argued that in

20

contrast to oxidative stress which is induced as a response to damaged molecules, redox
signaling always involves responses that are specific to oxidation reduction reactions.

Oxidative stress often initiates a number of varied responses ranging from cell
proliferation and transformation to apoptosis and senescence. The type of effect induced
depends on the types and amounts of ROS and reactive nitrogen species (RNS) that are
generated, the duration of the oxidative burst, the cellular antioxidant defense systems,
and the cellular context in which oxidative stress occurs. For example, low concentration
exposure of cells to hydrogen peroxide (H2O2) have been shown to mediate plateletderived growth factor (PDGF)-induced vascular smooth muscle proliferation 139, whereas
moderate concentrations of H2O2 induce growth arrest while high concentrations induce
apoptosis and/or necrosis140. Enzymes that are involved in oxidant generation or oxidant
scavenging are also critically involved in the regulation of cell growth141-144. It has also
been documented in several biochemical studies that, in most cancer tissue the levels/
activity of manganese superoxide dismutase and catalase are almost always low while
that of copper, zinc superoxide dismutase is usually low. Conversely, the activity of
glutathione peroxidase in tumor tissue is variable if measured with biochemical methods
using tissue homogenates145-148.These findings show an association between low
antioxidant levels vis a viz oxidative stress and cancer.

Chemistry of ROS
Presently, there are two main models of ROS signaling namely: (i) alteration of
intracellular redox state and (ii) oxidative modification of proteins7. In the alteration of

21

intracellular redox state, the cytosol is usually maintained in strong reducing conditions
often achieved by the redox balancing action of intracellular thiols like glutathione (GSH)
and thioredoxin (TRX).

Studies have shown that depending on their local environment, thiolates (S-) react with
H2O2 a lot faster than thiols (SH)149. It has also been established that in the active sites of
proteins like TRX and Prx one cysteine exists in the thiolate form making it more
amenable to reacting with H2O2. In the following redox reactions involving H2O2 and a
thiolate (RS-)61 (see fig. 1A), the sulfenate (RSO-) that is formed then reacts with a thiol
to form a disulphide bond (see fig.1B). Then the original thiolate is restored by exchange
with another thiolate (see fig 1C).

Oxidative modification of proteins
ROS can change the structure and function of proteins by modifying certain critical
amino acid residues, thereby inducing protein dimerization, and interaction with Fe-S
moieties or other metal complexes7. The most recognized oxidative modifications of
critical amino acids within the functional domain of proteins involve cysteine residues.
The sulfhydryl group (-SH) of a single cysteine residue may be oxidized to form sulfenic
(-SOH), sulfinic (-SO2H), sulfonic (-SO3H), or S-glutathionylated (-SSG) derivatives7, 150.
When the critical cysteine is located within its catalytic domain, an alteration of this
nature could vary the enzyme activity151. On the other hand, when the critical protein is
within the DNA-binding motif of a transcription factor, the ability of the transcription
factor to bind DNA is affected152. For example, the active site of all but one of the protein
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peroxiredoxin (Prx) contains cysteines out of which one is a thiolate (S-). Prx will react
with ROS to form sulfenic acid (see fig. 2A). A second thiol then reacts with the
sulfenate to form an intramolecular disulphide (see fig 2B). In the third and final step, all
but one Prx use TRX to restore the original thiolate (see fig 2C).

Redox signaling and its effect on signaling pathways
Oxidative and reductive stress can induce redox surges with a resultant change in the
thiol status of the proteins. Post-translational modifications of proteins or changes in the
thiol status of proteins due to changes in the redox environment of the cell are two of the
major pathways for signaling in cells. Characteristically, changes in the cellular redox
environment could result in modification of signal transduction, DNA and RNA
synthesis, protein synthesis, enzyme activation, as well as regulation of the cell cycle153155;156;157;137, 158, 159

.

A number of studies have shown that ROS and RNS have the ability to change or modify
several signaling pathways72, 160-165, 165. Among these pathways are the mitogen-activated
protein kinases (MAPK), which has been shown to be activated by both exogenous, and
receptor stimulated H2O2166; Protein tyrosine phosphatases (PTPs) and thioredoxin
(TRX). Modification of signaling pathways is possible because certain key proteins such
as PTPs and TRX contain essential cysteines which serve as targets for ROS and RNS167,
168

. Transcription factors like AP-1 and NF-kB, and Caspases are considered redox

sensitive because it has been biochemically demonstrated that their critical cysteines are
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in the thiolate form accounting for the ease with which they are oxidized and reduced by
oxidants and enzymes169-171.

The first evidence of reversibility of thiols oxidized by ROS and RNS was demonstrated
with PTPs at a time when PTPs were first recognized as important players in signaling.
Over the years, redox-mediated regulation of PTPs has been supported by several in vivo
studies. The following PTPs are known targets for ROS and RNS, PTP1B, SHP-2,
LMW-PTP, PTEN as well as CDC25172.

ROS induces the oxidative modification of Protein tyrosine phosphatases (PTPs)
Protein tyrosine phosphatases (PTPs) are important enzymes in the control of cell cycles
and signal transduction. They act in conjunction with protein tyrosine kinases to regulate
the phosphorylation of protein tyrosine in response to cellular signals173, 174. Many studies
have revealed that PTKs may be directly activated by the inhibition of PTPs by ROS 167,
175, 176

. Reversible inactivation of PTPs by ROS (especially H2O2) plays an important role

in redox control and cell signaling132. Based on the work done by Rhee’s laboratory, we
now know that stimulation of A431 cells with epidermal growth factor (EGF) leads to the
generation of H2O2 and a consequent inhibition of PTP1B70. Other biochemical studies
also showed that an increase in the production of intracellular oxidants could contribute
to enhanced tyrosine phosphorylation-dependent signaling, such as signaling in response
to growth factors70;66, by transiently stemming the enzymatic activity of members of the
PTP family, and promoting a burst of PTK activity177, 178. However, it is unclear if this
phenomenon is the same for every member of the PTP family.
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ROS and the cellular redox state are able to regulate the activity of PTPs. PTPs have a
functional motif that contains a constant cysteine residue, which acts as an electron donor
in catalysis179, 180. As a result of its unsually low pKa, the functional cysteine residue is
prone to oxidation and thus inactivation. Only oxidations that do not advance beyond
sulfenic acid (S–OH) are reversible181, 182. A vital requirement for regulating the activity
of PTPs (or any regulating molecule) is that the modification be specific and reversible.
However, the cysteine sulfenic acid formed at the active site of phosphatases can be
oxidized further to non-reversible cysteine-sulfinic acid and cysteine-sulfonic acid, within
the cell 183. This effect is believed to be countered by glutathionylation184.

Glutathionylation is a reaction of either cysteine or cysteine sulfenate with GSH within
the cell to form a mixed disulfide bond. The formation of a mixed disulfide between
PTP1B and GSH (or GSSG) would prevent irreversible oxidation of the active site
cysteine and provide for the reversible reduction either chemically or enzymatically.
Barrett et al. 185 have reported that PTP1B is inactivated by the formation of a mixed
disulfide with glutathione and that this inactivation is reversed not only by DTT but also
more importantly by thioltransferase, a thiol-disulfide oxidoreductase that is specific for
glutathionyl mixed disulfide substrates186, 187 and specifically utilizes GSH as cosubstrate188. The glutathionylation occurs on Cys215, the active site cysteine. This
mechanism suggests an alternative modification to the redox regulation of cysteine in
PTP1B and suggests a possible in vivo mechanism in the regulation of phosphatase
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activity. Also, reversible S-glutathionylation also appears to form the basis for redox
regulation of c-Jun DNA binding169.

PTP-1B is directly inactivated by ROS-induced reversible oxidation of its catalytic site,
Cys215, and this has been proposed as a mechanism for EGF-mediated mitogenic
signaling151; 189. Studies on B lymphocytes reveal that, following B cell receptor
activation, the ROS produced by DUOX1 enhance prompt generation of a signal by
reversible inhibition of SHP1, which then results in enhanced tyrosine phosphorylation
and activation of Lyn kinase 190. Superoxide radical has been shown to regulate the
activity of PTPs (especially PTP1B) very efficiently, again through cysteine residues 132.

Phosphatase and Tensin Homologue (PTEN) and Reactive Oxygen Species
The tumor suppressor PTEN (phosphatase and tensed homologue) regulates cell growth,
survival and migration by the removal of the 3’-phosphate of phosphoinositides. It has
been reported that the exposure of cells or purified PTEN to H2O2 resulted in inactivation
of PTEN in a time- and H2O2 concentration-dependent manner 167, 189, 191. As with other
phosphatases, H2O2 induces the reversible inactivation of PTEN through oxidation of the
essential Cys124 167; 192. This forms cysteine-sulfenic acid, which reacts with the socalled backdoor cysteine (Cys71 substrate) to form a disulfide. The disulfide formed is
then further reduced to its active form by thioredoxin (TRX)193.

Though the stimulation of various receptors induces H2O2 production, Lee et al.194
proposed that the receptor-mediated activation of phosphoinositide 3-kinase (PI3K) alone
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does not does not account for the accumulation of 3'-phosphorylated phosphoinositides,
and that the simultaneous inactivation of PTEN by H2O2 produced in response to receptor
stimulation might also be essential for this event195. A high frequency of PTEN mutations
and subsequent loss of function has been reported in several tumor types like endometrial
carcinoma, brain, and breast cancer196. It is documented the loss of PTEN function results
in an increased Akt activity and, subsequently, cell survival197. Evidence exists that
inactivation of PTEN by oxidation might be a physiological mechanism for regulation of
this enzyme, not only by oxidative stress, but by ROS produced in other circumstances
such as the stimulation of cells by growth factors 198, 199.

The cyclin-dependent kinase inhibitor p27Kip1, a target of Akt, has been proposed as a
downstream mediator through which PTEN may positively regulate cell cycle
progression200. In prostate cancer, 16–68% of the cases show an association between the
low grade expression or loss of p27 protein with either adverse or impaired prognosis201204;205

.

CDC25 Phosphatases and Reactive Oxygen Species
Cdc25 phosphatases also known as the dual-specificity phosphatases, are key activators
of the CDK/cyclin complex, hence they serve as regulators of normal cell division. There
are three isoforms of Cdc25, namely Cdc25A, Cdc25B, and Cdc25C. These three
phosphatases function to dephosphorylate the CDK/cyclin complex on pThr14 and/or
pTyr15 residues, counteracting the phosphorylating effect of the Weel and Myt1 kinase.
This dephosphorylation prompts the ultimate activation of CDK/cyclin activity during
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normal cell cycle progression206, 207. Cdc25A controls both the G1-to-S and G2-to-M
transitions, whereas Cdc25B and Cdc25C are regulators of the G2-to-M transition.

The Cdc25 phosphatases also play an important role in the checkpoint response that
prevents CDK/cyclin activation following DNA damage208, 209. Confirming an important
role for the Cdc25 phosphatases in cancer, Cdc25A and Cdc25B, but not Cdc25C, are
over expressed in many different primary human cancers210.

Like all other PTPs Cdc25 phosphatases have two cysteine molecules in their functional
site. One of the cysteines exists in the very reactive thiolate (S-) form while the other one
exists as a less reactive thiol. The thiolate in Cdc25’s functional motif has been shown to
be oxidized by low concentrations of ROS resulting in the formation of a reversible
cyseine-sulfenic acid (see eqn 13). The resultant sulfenic acid then forms a mixed
disulfide bond with the second thiol to prevent further oxidation by ROS to an
irreversible sulfinic acid. The reduction of the disulphide bond to the original thiolate is
carried out by either TRX or GSH. H2O2 causes oxidation of the active site cysteine
residue in Cdc25- PTP, with a subsequent binding to 14-3-3 proteins for nuclear export
and subsequent degradation211; 212, 213. Oxidative stress has also been shown to induce the
nuclear export of Cdc25B through protein kinase B/Akt-dependent phosphorylation on
Ser353 214.

An association between mitogenic signaling and the cell cycle mechanism has been
suggested by studies which showed that the tyrosine phosphatase Cdc25A, among others,
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could have an effect on Raf-1, a key component of the MAPK pathway215, 216. In 1995,
Conklin et al. showed that Raf-1, which is known to bind 14-3-3 proteins, appeared to
associate with Cdc25A and stimulate its phosphatase activity217. Galaktionov et al. 218
also showed an association between the Cdc25 phosphatase and Raf-l in somatic
mammalian cells and in meiotic frog oocytes. These authors also suggested that
activation of the cell cycle by the Ras/Raf-l pathways might partially be mediated by
Cdc25. Another study also showed that dephosphorylation of Raf-1on tyrosine by
Cdc25A resulted in a significant decrease in the kinase activity of Raf-1219, and
consequently of ERK. On the flip side, this implies that inactivation of CDC25A could
lead to an increase in the kinase activity of Raf-1 and thus the phosphorylation and
activation of ERK.

Recently, a study by Vogt et al.220 showed that overexpression of Cdc25A in whole cells
resulted in the dephosphorylation of ERK, which was reversible by an inhibitor of
Cdc25A (2-mercaptoethanol)-3-methyl- 1,4-naphthoquinone (compound 5). The high
point in this study is that a Cdc25 inhibitor increased phosphorylation and nuclear
accumulation of ERK thereby underscoring the proposition that Cdc25A regulates the
phosphorylation state of ERK. More recently, in addition to showing a physical
interaction between Raf-1 and Cdc25A, Nemoto et al. 221 were also able to show that the
phosphatase Cdc25A regulates Raf-1/MEK/ERK kinase activation in human prostate
cancer cells. Additional work done by Wang et al.222 suggested that phospho-ERK is
possibly another substrate of Cdc25A. Based on the above studies, one can infer that the
oxidation (downregulation) of CDC25A by ROS (which renders Cdc25A inactive) may
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also result in the phosphorylation of ERK that could ultimately phosphorylate a number
of transcription factors, as well as the CDK inhibitor p27.

Mitogen Activated Protein Kinase- Phosphatase (MKPs) and Reactive Oxygen
Species
These are dual specificity phosphatases which have the ability to inhibit the mitogen
activated protein kinases (MAPKs) in several cell types223-229. Like other dual specificity
phoshatases, mitogen activated protein kinase phosphatases (MKPs) have recently been
added to the redox sensitive phosphatases list. Seth and Rudolf 230 showed that, like
other PTPs, MKPs are able to form cysteine-sulfenic acid upon oxidation by ROS. Unlike
other PTPs, however, the sulfenic acid formed does not form a disulfide with proximate
cysteine or sulfenyl amide bond species with neighboring residue, but rather utilizes
various cysteines distributed in both the N-terminal substrate-binding domain (Cys147 in
particular) and the C-terminal catalytic domain (Cys218) to protect its active site from
further oxidation.

MAPKs play a central role in mediating intracellular signaling events triggered by
mitogens, growth factors, and stress231, 232. The MAPKs are activated by specific
upstream dual specificity kinases (MAPK kinases, MKKs) through phosphorylation on
both threonine and tyrosine residues in the TXY motif. Extracellular stimuli activate
MAPKs leading to the phosphorylation of an array of cellular substrates and nuclear
transcription factors.
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In mammals, three distinct MAPK families have been studied extensively. The
extracellular signal-regulated kinase (ERK) family is activated by growth and
differentiation factors and by phorbol esters 233. The c-Jun NH2-terminal kinase (JNK)
family (or stress-activated protein kinase (SAPK) and p38 MAPK families are activated
by pro-inflammatory cytokines and environmental stress. It is noteworthy that the three
aforementioned subgroups of MAPKs have been implicated in both cell growth and cell
death, hence the need to tightly regulate these pathways is principal in determining cell
fate234. Therefore the injurious effect of non-stop activation of MAPK pathways may
include excessive production of MAPK-regulated genes, uncontrolled proliferation, and
unscheduled cell death 235.

A number of cellular stimuli that induce ROS production are also capable of activating
MAPK pathways concurrently, in multiple cell types. This was established by studies
which showed that prevention of ROS accumulation by antioxidants blocks MAPK
activation after cell stimulation with cellular stimuli235-237. Additionally, it has been
documented that direct exposure of cells to exogenous H2O2, to imitate oxidative stress,
resulted in the activation of MAPK pathways238, 239. Though the mechanism(s) by which
ROS can activate the MAPK pathways, is still not well defined and because ROS can
change protein structure and function by modifying critical amino acid residues of
proteins7, 238, 239, we could therefore infer that the oxidative modification of signaling
proteins by ROS may a probable mechanism for the activation and or inactivation of
MAPK pathways.
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The Effect of ROS on Transcription Factors
AP-1 and NFκB
The tumor progression stage of carcinogenesis has been shown to be modulated by
transcription factors such as activator protein-1 (AP-1) and nuclear factor-kappaB
(NFκB). A causal relation has been well documented between neoplastic transformation
and transcription factor AP-1 transactivation 240-243. Infact, a constitutive increase of AP-1
activity has been associated with the malignant conversion of papillomas to carcinomas
244

. There is an increase in NFκB transactivation during tumor progression 245.This NFκB

transactivation is also increased by agents that elevate AP-1 activity during tumor
progression while its inhibitors also attenuate AP-1 activity 246, 247 suggestive of common
upstream signaling cascades that mediate elevated AP-1 in addition to NFκB
transactivation during tumor progression.

ROS have been shown to act as activators of transcription factors which modulate their
activity either directly or indirectly by activating other signaling cascades. NFκB
transactivation is considered redox sensitive because (i) The phosphorylation of its
inhibitor I-κB is mediated by oxidation; and (ii) the Ref/thioredoxin-dependent binding of
the p50 subunit to the DNA is controlled by the reduction of an essential cysteine group
248

(cite article). NFκB activation can be be induced by several activators/oxidants in the

absence of any physiological stimulus and is inhibited by a wide range of antioxidants 249251

. On the other hand AP-1 DNA binding activity has also been shown to be modulated

by Ref/thioredoxin-dependent reduction of cysteines in c-Jun and c-Fos 252.
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Persistently high ROS levels activate redox-sensitive transcription factors, such as
nuclear factor-kappaB (NF-κB) and activator protein-1 (AP-1), which may then act as
molecular switches that convert normal cells into premalignant cells, with ensuing clonal
expansion to form solid tumor253. Hence, abnormal activation of NF-κB and AP-1, which
results in the transcriptional activation of genes involved in inflammation, cellular
proliferation, and growth, has been implicated in pathophysiology of various
malignancies 253, 254.

Mitogen-activated protein kinases (MAPKs) have been shown to modulate transcription
factor activities in addition to being part of kinase cascades that serves as transmitters
connecting extracellular stimuli to specific transcription factors thus allowing these
signals to regulate specific gene expression. Studies have shown that JNKs and p38
MAPK are a part of the stress response pathways activated by cellular stress induced by
agents like heat, UV and ionizing radiation and inflammatory cytokines mediating
inhibition of cell proliferation or cell death 255, 256. AP-1 activity has been shown to be
modulated by MAPKs in response to various stimuli257. NFκB activation has been
reported to be modulated by MEKK1, a kinase upstream of JNKs 258 as well as p38
MAPK 259. There is evidence that antioxidants can attenuate MAPK activation 6, 255, 260,
thereby suggesting that MAPK signaling cascades are additional targets affected by ROS
levels in cells.
NRF-1
Nuclear respiratory factor 1(NRF-1) is a protein that encodes genes that code for a
phosphorylated nuclear protein with a bZIP domain. The encoded protein forms a homo-
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or heterodimer, which functions as a transcription factor that activates the expression of
some key metabolic genes. These key metabolic genes regulate cellular growth and
nuclear genes required for respiration, heme biosynthesis, mitochondrial DNA
transcription and replication261, 262 Initially, NRF-1 was described as an activator of
cytochrome c expression and afterwards was found to act on many nuclear genes essential
for mitochondrial respiratory function263, 264 such as genes encoding respiratory subunits
265

, the rate-limiting heme biosynthetic enzyme266 as well as mtDNA transcription and

replication factors267, 268.

NRF-1 binds to the antioxidant response element (ARE) in the promoters of genes which
are involved in response to cellular stress269 to induce the expression of phase II
detoxifying enzymes and oxidative stress-inducible proteins, like NADPH, quinone
oxidoreductase, and glutathione S-transferaseA2 270, 271. Studies have shown that NRF-1’s
ability to regulate the ARE of stress-related genes and TNFα is based on its interaction
with transcription factors such as AP1 proteins (c-Jun, JunB, and JunD)272, 273. In
addition, NRF-1 has been shown to play an important role in cellular growth and
differentiation274, 275. A biochemical study by Chang et al276. implicated NRF-1 protein
with the regulation of neurite outgrowth.

Studies have shown that NRF-1 is phosphorylated both in vivo and in vitro on serine
residues within a concise amino-terminal domain277. The phosphorylation of these sites in
vitro augments NRF-1 DNA binding action, surmising the capacity of such modifications
to regulate NRF-1 function. Herzig et al.278 showed that the activity of NRF-1 is
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enhanced by phosphorylation, which occurs in cells that have been stimulated with
serum. It is assumed that a phosphorylation such as this allows the nuclear transcriptional
apparatus to respond both to extracellular signals and intracellular ATP concentrations in
controlling the expression of the respiratory chain278. The post-transcriptional
modification of the N-terminus of NRF-1 has been shown to play an important role in
controlling DNA-binding activity277. It has been established that P/CAF, which is a
p300/CBP (cAMP response-element-binding protein (CREB)-binding protein)-associated
factor, can interact directly with the N-terminal domain of NRF-1 and modify it by
acetylation. The ensuing modification significantly stimulates the DNA-binding activity
of NRF-1279. A study by Cho et al.280 showed that the methylation on the NRF-1 sites
may be a means of silencing the Tfam promoter with an ensuing decrease of
mitochondrial biogenesis281. According to Narayanan et al.282 NRF-1 often exists as a
complex with Keap1 (inhibitor) but as a result of stress, NRF-1 separates from Keap1 and
becomes active.

NRF-1 and 17 β-Estradiol (E2)
Estrogen increases the transcription of NRF-1283, 284. Results of work done by RodríguezCuenca et al.285 show that E2 appears to affect the mitochondrial biogenic program in two
ways. The first is inhibiting it through the downregulation of NRF-1, gabpa, and tfam
mRNA286; or second, downregulating PTEN mRNA levels in cell-cultured brown
adipocytes, implying an activation of the PI3K-Akt pathway and therefore a
mitochondrial recruitment-stimulatory signal. E2 has been shown to inactivate PTEN
activity by phosphorylation and, hence, influence PTEN activity, suggesting both a
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chronic and an acute control mechanism of PTEN by estrogens 287. Felty et al. 288 showed
that E2-induced oxidants increase the transcriptional activity or binding of AP-1, CREB,
and NRF-1 to their individual DNA response elements. The study actually showed that at
physiological concentrations E2 stimulates a rapid production of intracellular ROS
resulting in the phosphorylation of c-jun and CREB as well as increased activity of
redox-sensitive transcription factors NRF-1, c-jun, and CREB, which are known to be
involved in the regulation of cell cycle genes289.

NRF-1 and Cancer
Xu et al. 290 have been able to demonstrate a connection between cancer and NRF-1,
based on the result of a study which observed changes in NRF-1LKO (NRF-1 liver
knock-out ) livers. The livers were characterized initially by cell death, proliferation, and
inflammation, followed by the appearance of dysplastic cells and eventually cancer. The
X gene of hepatitis B virus (HBV) which is one of the chief factors in HBV-induced
hepatocarcinogenesis is necessary to achieve a productive HBV replication in vivo.
Recently, Tokosumi and others291 showed that NRF-1 exclusively binds the 21-bp
minimal promoter and contributes to transcription of the X gene. They also suggested that
concurrent activation of the X gene and mitochondrial genes by NRF-1 may allow the X
protein to target mitochondria most efficiently292. A study by Auf dem Keller et al. 293
showed that NRF-mediated gene expression in keratinocytes is dispensable for wound
healing but crucial for skin tumor prevention.
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NRF-1 and cell cycle
The transition of cells from quiescence (G0) to proliferation (G1) increases the cellular
energy (ATP) demand. The cell responds to this increase in demand for ATP by
modulating the activity of the respiratory chain components, and it is the duty of NRF-1
to regulate the expression of a number of genes required for mitochondrial respiratory
function 264.

A recent study demonstrated that NRF-1 activity is enhanced by phosphorylation upon
serum-induced proliferation, leading to transcriptional induction of cytochrome c, a major
component of the respiratory apparatus294. The induction of cytochrome c was associated
295

with enhanced energy production by the mitochondria in preparation for entry to the

cell cycle.

Results from work done by Herzig et al. 296 show that NRF-1 functions to induce gene
expression and maintain the level of cytochrome c in actively dividing cells. Additionally,
the results also suggested the possibility that activated NRF-1 may contribute to the
synthesis of other respiratory chain constituents later in the cell cycle. It can therefore be
inferred that the phosphorylation of NRF-1 may be a significant regulatory event in the
transition from quiescence to active cell division.

Virbasius et al. 297 showed that NRF-1 sites are found in genes that may be directly
involved in cell cycle regulation (like cdc2, RCC1) or are regulated by cell growth (like
omithine decarboxylase, DNA polymerase-a, and GADD153). Their study concluded that
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even though the most current and best defined biological role for NRF-1 is in the nuclear
control of mitochondrial function, the NRF-1 protein or related proteins having the NRF1 DNA-binding domain may possess the ability to integrate various functions required for
cell maintenance, growth, and proliferation.298

NRF-1 has been shown to mediate the apoptotic function of c-myc in a study which also
shows that cytochrome c and other nuclear-encoded mitochondrial genes are also
regulated by NRF-1 and provides evidence of a link between the induction of NRF-1
target genes and sensitization to apoptosis on serum depletion299. The finding by Felty et
al. 300 that E2-induced mitochondrial ROS control the expression of early G1 phase genes
(Felty and Roy, unpublished results), imply that E2-induced ROS increase the
transcriptional activity or binding of AP-1, CREB, and NRF-1 to their respective DNA
response elements responsible for the expression of early cell cycle genes. Based on
previous studies (already mentioned in this review) which showed that redox-sensitive
transcription factors c-jun, CREB, and NRF-1 regulate cell cycle genes262, 301, 302, Felty et
al.’s finding could be a pointer that E2-induced ROS may play a role in cell cycle
progression of estrogen-dependent cells 303.

NRFI and ROS
A study by Suliman et al.262 showed that ROS signaling is necessary for hepatic
mitochondrial biogenesis accompanying cell proliferation, which is linked to activation of
pro-survival PI3K-Akt pathways. The PI3K-Akt pathway in turn leads to NRF-1
activation and subsequent DNA binding. Furthermore, ROS originating in mitochondria,
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cytoplasm, or outside the cell could activate Akt and promote NRF-1 translocation.
Hence, PI3K-Akt activation may regulate both mitochondrial biogenesis and cell
proliferation after oxidative stress.

Already mentioned in this review is the fact that cysteine-dependent phosphatases, like
PTEN, which are reciprocal regulators of PI3K, are sensitive to inactivation by oxidants.
This is substantiated in a recent study by Piantadosi and Suliman 304, which provided
evidence that the stimulation of PI3K by extracellular oxidants activate Akt and promote
NRF-1 phosphorylation as well as nuclear translocation. NRF-1 phosphorylation
increases its ability to stimulate transcription of Tfam, a downstream nuclear-encoded
gene for a mitochondrial protein required for mtDNA transcription and replication.

Based on work done on HeLa cells, Miranda et al.305 have been able to show that cells
depleted of mitochondrial DNA (ρ0) have an increased amount of intracellular ROS, and
that under these conditions, NRF-1 and Tfam are up regulated, further supporting the
postulated role of ROS in mitochondrial signaling to the nucleus. NRF-1 has also been
found to play a role in the regulation of genes involved in glutathione synthesis, therefore
signifying a basis for an equally low GSH concentration and reduced stress response in a
study which also found that interference with the NRF-1 gene results in hypersensitivity
of fibroblasts to the noxious effects of various oxidizing agents306. Work done by Chen et
al. 307 showed that NRF-1 may be required to protect fetal liver cells from endogenous
TNF-induced apoptosis. The study concluded that NRF-1 plays an important role in
maintaining redox balance in the fetal liver cells signifying a cell-specific and
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developmental stage-specific function of NRF-1 in protecting liver cells from apoptosis
during development.

Cell Cycle
Cell cycle control
Simply put, a cell cycle refers to a programmed life cycle of a dividing cell. The process
of cell-cycle transition can be divided into four phases: the G1 phase, where mRNA and
proteins are synthesized in preparation for DNA synthesis; the S phase where DNA
synthesis occurs; the G2 phase, where mRNA is synthesized in preparation for the fourth
phase, mitosis (M phase). Quiescent cells are found in the G0 phase and exhibit minimal
mRNA and protein synthesis. Stimulation of quiescent cells (G0) results in their entry
into the G1 phase which in turn induces a number of proteins that regulate and control
cell growth and proliferation 229;308.

In addition to the four cell cycle phases, there are two main checkpoints that regulate cellcycle progression. The G1/S checkpoint prevents the replication of damaged DNA. This
checkpoint is regulated by a balance between growth-stimulating and growth-inhibitory
responses. The second checkpoint, which is G1/S to G2/M checkpoints control the
sequence and timing of cell-cycle transitions, enabling the assimilation of cell division
with environmental stimuli as well as the monitoring of DNA damage to maintain
genomic integrity. An additional spindle assembly checkpoint functions to delay mitosis
until the mitotic spindle is correctly formed 309.
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The cell cycle process is controlled by the following proteins: The cyclins, namely
cyclins A, D, and E; the cyclin dependent kinases CDK2, 4, and 6; the cyclin kinase
inhibitors (CKIs), namely p16INK4a (p16), p21CIP1/WAF1(p21), and p27; and other negative
regulators such as the retinoblastoma protein (Rb) and p53, which regulate the effects of
both CKI p21 and cyclin A protein310. During the G1phase, cyclins D1 and E are rapidly
synthesized and bind to CDK4 and CDK2, respectively. The resulting cyclinD-CDK4/6
complex then phoshorylates the retinoblastoma protein (Rb). Phosphorylation of Rb
releases E2F which mediates gene expression and the induction and the formation of
cyclin E- CDK2 complex.

The cyclin E- CDK2 complex phosphorylates a broad variety of proteins, including Rb
with a consequent release of E2F, which promotes cell-cycle progression to late G1,
leading to the induction and formation of the cyclin A/CDK2 complex.

The cyclin A/CDK2 complex functions to advance cell-cycle progression through the
G1/S phase, into S, as well as late S and S/G2 interphase (cyclin A/CDK1). Cyclin
A/CDK1 collaborates with Cyclin B/CDK1 to regulate G2 to M phase transition. In its
phosphorylated state, cyclin B complex is inactive and requires dephosphorylation on Tyr
15 by CDC25 to activate it. The active cyclin B complex promotes cell division (M
phase)229.

The active cyclin D complex is inhibited by CDK inhibitor p16 to induce early G1 arrest
and prevent the phosphorylation of Rb. It has also been shown that •NO has the potential
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to induce p21, leading to the inhibition of the action of cyclin E complex. Proliferating
cell nuclear antigen (PCNA), a cofactor for DNA polymerase is negatively regulated by
p21 311. Inhibition of CDK2 activity by p27 can prevent the phosphorylation of
transcription factors critical for entry into the S phase 312. In G2, p53 can induce late G2
arrest (inhibition of active cyclin B action) or mediate early G2 arrest via p21 inhibition
of Cdc25.

The role of p27 in cell cycle control
The CDK inhibitor p27 has a negative effect on the activity of CDK2-cyclin complexes
during G1 phase and CDK1 (Cdc2) complexes during G2 phase. In breast cancer, cyclins
D1 and E, in addition to the cyclin-dependent kinase inhibitors p21 and p27, play very
important roles in cell-cycle control and as potential oncogenes or tumor suppressor
genes. Reduced expression of p27 has been associated with the poor survival of cancer
patients313.
In breast cancer cells, CDK inhibitors are regulated following mitogenic stimuli such as
activation of receptor tyrosine kinases and steroid hormone receptors. Their deregulation
frequently impacts on breast cancer outcome, including response to therapy314. The
expression of p27 is regulated through transcriptional and translational control
mechanisms, by modulation of both protein stability and changes in subcellular
localization.

According to Medema et al. 315, even though the transcription of the p27 gene is regulated
by factors like AFX-like Forkhead transcription factors, the abundance of p27 during the
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cell cycle is mostly mediated post-transcriptionally. As cells exit quiescence and progress
into S phase, the levels of p27 protein decline as a result of decreased translation of p27
mRNA and targeted proteolysis316.

In the G1 and S phase, degradation of p27 is regulated by two RING-finger E3 ubiquitin
ligase-containing complexes with contrasting subcellular locations. These complexes
respectively ubiquitylate p27 and target it for proteosomal degradation. In addition to
promoting p27 degradation, phosphorylation also regulates p27 subcellular localization.
Following mitogen stimulation, this p27 is likely to be phosphorylated on serine 10 by
human kinase-interacting stathmin (hKis), which promotes nuclear export317. According
to work done by Liang and Slingerland, 318 p27 is also phosphorylated on two threonine
residues, Thr157 and Thr198, by Akt, which results in the cytoplasmic retention of p27 .
The resultant cytoplasmic localization following the phosphorylation of p27 at Thr157 is
due to inhibition of its nuclear import. Overall, this suggests a model in which mitogenic
signaling pathways promote cytoplasmic localization of p27 and its subsequent
degradation by the Kip1 ubiquitination-promoting complex (KPC). This will increase the
activity of nuclear cyclin E-CDK2 resulting in p27 Thr187 phosphorylation and
degradation of p27, leading to a positive feedback loop for enhancement of cyclin ECDK2 activity.

Sakakibara et al. showed that the ERK subfamily of MAPK is both essential and
adequate in the regulation of p27 and a number of other studies have also established that
ERK activity also contributes to the down-regulation of p27 319; 320-324.
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The effects of ROS on regulators cell cycle
There is increasing evidence suggesting that ROS and RNS play a part in the regulation
of cell proliferation and cell-cycle control. Studies have shown that there is a significant
similarity between the pathway that regulates cell cycle progression and the one that
regulates the induction of apoptosis. These similar pathways are intimately
interconnected by critical regulatory molecules and signal transduction cascades325.

Reactive oxygen and nitrogen species have a wide range of effects on cell-cycle
advancement. The growth-inducing actions of ROS/RNS may be exerted via the
activation of kinase signaling cascades, redox regulation of tyrosine phosphatases, and
direct activation of transcription factors144.

Low concentrations of H2O2 increase cell proliferation through increased cyclin D
expression and G1/S transition in fibroblasts326 and by means of decreased expression of
p27 in prostate tumor spheroids327. Arnold et al. 328 have also shown that H2O2 mediates
cell growth and cell-cycle regulation caused by targeted overexpression of the Nox1
subunit of the NADPH oxidase328. The ability of ROS to promote the G1/S transition is
further substantiated by the finding that treatment with antioxidants will repeatedly block
proliferation and cell-cycle progression. This can be corroborated by the work of Menon
et al. 329, which showed that the antioxidant N-acetyl-L-cysteine induces G1 arrest by
decreasing cyclin D1, increasing p27 protein levels, and leading to hypophosphorylation
of Rb329. It is also noteworthy that low to moderate ROS can induce MAPK pathways
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that lead to cell growth and proliferation, whereas high ROS induce DNA damage and/or
MAPK pathways that activate p53, cell arrest, and apoptosis326.

Growth arrest associated with higher, sustained levels of ROS and RNS appears to
involve the induction of inhibitory cell-cycle control proteins, especially p21, and the
repression of cyclins330. More recently, the redox-sensitive family of Forkhead box class
O (FOXO) transcription factors has been shown to promote cell-cycle arrest in G1 by
transcriptional up-regulation of the CDK inhibitor p27 and down-regulation of cyclin
D1331.

Very little is known about the redox control of the spindle assembly checkpoint. It has
recently been suggested that mitotic spindle pole formation is an important component of
H2O2 -induced mitosis in type II pneumocytes 332. Cdc2 and other mitotic protein kinases
have also been shown to play a role in spindle regulation,333 suggesting a possible role of
redox control of Cdc2 activation by Cdc25C in the spindle checkpoint. The MAPK
pathways, especially p38 and ERK1/2 ,334 which are regulated by ROS appear to play a
key role in mitotic spindle assembly.
The role of Redox signaling in Anti estrogen Resistance
Based on the above review, we may therefore infer that redox signaling could contribute
to anti-estrogen resistance by the following biological processes: induction of ROS by
anti-estrogens and a subsequent inactivation of PTPs or MKPs resulting in the activation
and hyper-stimulation of either the MAPK pathway or the PI3K/Akt pathway, which
could either affect the cell cycle through the activation of transcription factors or the
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CDKI leading to a change from the tamoxifen sensitive phonotype to a tamoxifen
resistant one.

Cancer cells are characterized by uncontrolled proliferation and altered energy
metabolism. In response to the activation of many oncogenes, continuous mitogenic
signaling augments the production of ROS. Additionally, mitogens like estrogen and antiestrogens such as tamoxifen have been shown lead to ROS production when they are
exposed to cancer cells both in vitro and in vivo. The ROS and redox signaling that ensue
result in the induction of replication stress and DNA damage response, which in
conjunction with the functional checkpoint, induces senescenes, often considered a
barrier to tumorigenesis 335, 336. Interestingly, once cancer cells have escaped the
mechanisms that counteract mitogenic signaling, they advance to a pro-oxidative state
typified by unbridled proliferation and altered energy metabolism, including defects in
mitochondrial respiration.

Defects in mitochondrial respiration cause inactivation of PTEN in a redox-dependent
manner and activation of the pro-survival factor Akt 337. Akt is one of the kinases that
phosphorylate p27 on the threonine 157 position resulting in cytoplamic sequestration of
p27 with an ensuing loss in its cyclin kinase inhibitory function; a consequent
unrestrained cell proliferation and a change from a tamoxifen sensitive to a tamoxifen
resistant phenotype. Futhermore, activated Akt has been shown to phosphorylate the
redox sensitive transcription factor NFR-1 thereby activating it and leading to its binding
to the promoter region of cell cycle genes338.
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It is also probable that NRF-1 could be part of a pathway that connects the mitogenactivated signaling cascade (either the MAP kinase or the PI3K Akt pathway) to cell
cycle progression. Following ROS production and the induction of a pro-oxidative state
in cancer cells, PTPs are oxidized in a redox dependent manner, rendering them unable to
carry out their usual function. In the case of Cdc25A this function is to inactivate the
MAPKKK Raf-1, with which it has been shown to have an on/off switch like
relationship339. The inability of oxidized Cdc25A to inactivate Raf-1 results in a
continuous activation of the MAP kinase pathway, with a consequent upregulation and
nuclear translocation of ERK. The nuclear translocation of ERK enables it to
phosphorylate NRF-1 protein causing it to bind to the promoter of certain cell cycle genes
(unpublished work done in Dr Roy’s lab) inducing their transcription and promoting cell
proliferation.

Tumor suppressor genes also play an important role in linking metabolism to cell growth.
A central regulator of metabolism is the PI3K/AKT pathway, which controls metabolism
through several mechanisms, including enhancement of protein translation through
mTOR340. The c-Myc oncoprotein also plays a vital role in regulating metabolic changes
required for cell division341. Furthermore, the pro-oxidative state of cancer cells is
typified by adjustive responses that include changes in the expression of antioxidant
enzymes and increased production of GSH. Together the interconnected disturbance in
metabolism and oxidant production common to most tumor cells provide therapeutic
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opportunities that do not depend on targeting a single oncogene or tumor suppressor
gene.
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Figures and Legend
Figure1-R

Redox reactions involving hydrogen peroxide (H2O2 ) and a thiolate (RS-). Thiolate
reacts easily with H2O2 forming a sulfenate (RSO-) (see 1A), the sulfenate that is formed
then reacts with a thiol to form a disulphide bond (see 1B). Then the original thiolate is
restored by exchange with another thiolate (see 1C).

Figure 2-R
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The oxidation of Prx by H2O2. Prx reacts with H2O2 to form a sulfenate (fig.2A). A
second thiol then reacts with the sulfenate to form an intra-molecular disulphide (fig.2 B).
In the third and final step, TRX used to restore the original thiolate (fig. 2C).

Figure 3-R

Reversible PTP inactivation by H2O2. In step 1, an active PTP containing a thiolate
reacts with H2O2 to form an inactive but reversible PTP-sulfenate (SO-). In step 2, the
PTP-sulfenate reacts with GSH within the cell to form a mixed disulfide bond which
would prevent irreversible oxidation of the active site cysteine and allow for the
reversible reduction. In step 3, the mixed disulfide bond on the inactive PTP is reversed
back to a thiolate and PTP becomes active again.
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Figure 4-R

The effect of E2-induced ROS on regular mitogenic signaling. E2 crosses the cell
membrane and goes to the mitochondrium where it induces ROS formation. The oxidants
formed inhibit PTEN rendering it unable to inhibit the PI3K/Akt pathway resulting in the
hyper-stimulation of the pathway and a continuous phosphorylation of Akt.
Phosphorylated Akt then activates NRF-1 by phosphorylation enabling the now active
protein to binds to the promoter region of certain cell cycle genes.
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Figure 5-R

The effect of tamoxifen-induced ROS on regular mitogenic signaling. Tamoxifeninduced oxidants inhibit PTEN rendering it unable to inhibit the PI3K/Akt pathway
resulting in the hyper-stimulation of the pathway and a continuous phosphorylation of
Akt. Phosphorylated Akt then activates NRF-1 by phosphorylation enabling the now
active protein to binds to the promoter region of certain cell cycle genes.

III

REDOX SIGNALING CONRIBUTES TO THE DEVELOPMENT OF
TAMOXIFEN RESISTANCE IN BREAST CANCER TREATMENT

Abstract
Tamoxifen is a selective estrogen receptor modulator (SERM) which is used to treat
estrogen receptor positive (ER+) breast cancer. It is also used in breast cancer prevention
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and as an adjuvant in early breast cancer cases. Only about 70% of breast cancer patients
will initially respond to tamoxifen treatment. About 40% of patients who were initially
responsive to the drug and majority of the patients with metastatic breast disease will
develop resistance over time. Therefore the problem of tamoxifen resistance has been a
major setback in the otherwise successful treatment of ER+ breast cancer patients.
Although there has been an improvement in our current understanding of the molecular
mechanism(s) that result in the development of tamoxifen resistance, there is still a lot of
ground to cover on the subject. In this study we explored the role of Reactive oxygen
species (ROS) in the evolution of tamoxifen sensitive breast cancer to tamoxifen resistant
breast cancer. ROS are products of cellular metabolism which have been shown to induce
oxidative stress. An excessive and/or sustained increase in ROS production has been
implicated in the pathogenesis of cancer. Furthermore, ROS induced oxidative stress has
been shown to initiate various cellular responses including cell proliferation and
transformation; alteration of intracellular redox state and the oxidative modification of
certain signaling proteins resulting in the post translational modification of their
downstream targets. Interestingly, like estrogen, tamoxifen has been shown to induce
ROS formation, making it probable that tamoxifen induced ROS generated as a result of
prolong tamoxifen treatment of breast cancer patients may play a vital role in the
development of its resistance. Using tamoxifen resistant LCC2 cell and standard
laboratory techniques, we examined the role of ROS in the evolution of breast cancer
from a tamoxifen sensitive phenotype to a resistant one. We were interested in finding
out how and if ROS induces the post translational modification of p27 resulting in the
loss of its inhibitory function and if this process can be reversed by pre-exposing the cells
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to biological or chemical antioxidants. We discovered that, as a result of tamoxifen
exposure, an increasingly pro-oxidant environment induced cell proliferation by
diminishing p27 expression and increasing its phosphorylation on Threonine157 and
Threonine187. This is accompanied by an ensuing reduction of p27 binding to Cyclin
E/Cdk2 complex and loss of p27 stability culminating in the loss of sensitivity to
tamoxifen. We also found that Pre-exposing cells to either biological or chemical antioxidants, restored tamoxifen sensitivity by reversing the previous expression and
phosphorylation of p27.

Introduction
Tamoxifen resistance has remained a major setback in an otherwise successful treatment
of estrogen receptor positive (ER+) breast cancer. Most breast cancers are estrogenreceptor positive (ER+). Approximately 70% of patients with ER+ cancer will respond to
anti-estrogen therapy, such as tamoxifen1. In addition, a significant number of tumors that
initially respond to tamoxifen treatment often progress into a resistant phenotype over
time, in spite of sustained expression of ERα 2, 3.

Over the years, several pathways and postulates have been proposed and examined as
possible mechanisms of breast cancer resistance to tamoxifen. While some of these have
translated into beneficial therapies to a large number of patients, tamoxifen resistance still
remains a significant problem. In addition, though studies have examined the roles of
ERα and β, and their co-regulatory proteins; growth factor receptors and the activity of
their downstream kinases; Cas/c-Src/BCAR3 and cell cycle regulators like Cyclins D/E
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and p27, currently there is no study investigating the effect of Reactive oxygen species
(ROS) on p27 in tamoxifen resistance.

Cancers have been shown to be under persistent oxidative stress 4. Oxidative stress,
which is triggered by an imbalance between the production and detoxification of ROS,

5

has been implicated in the therapeutic resistance to tamoxifen 6. Tamoxifen, a selective
estrogen receptor modulator (SERM), has been reported to possess both pro- and antioxidant properties. Among its antioxidant actions are: its cardio-protective effect in the
prevention of atherosclerosis

7, 8

; its inhibition of lipid peroxidation

9

and its ability to

protect low density lipoproteins (LDL) against copper ion-mediated oxidative damage

10

in humans. Conversely, its pro-oxidant effects include its ability to induce oxidative liver
damage

11

and its explication as a hepato-carcinogen in rodents due to ROS over-

production that occurs during its metabolism

12, 13

. Additionally, it has been suggested

that oxidative stress might trigger the pathogenesis of tamoxifen-induced toxicity

14

.

Though it has not been ascertained whether the elevated oxidative state of tamoxifen
resistant breast cancer is due to prolong tamoxifen exposure, the possibility that the prooxidant property of prolonged tamoxifen exposure may play a role in breast cancer
resistance cannot be ignored.

Reactive oxygen species consist of a number of partially reduced metabolites of oxygen
such as superoxide anions (O2− •), hydrogen peroxide (H2O2), and hydroxyl radicals
(OH·), characterized by higher reactivity than molecular oxygen. These reactive species
are known to play a vital role in cell growth mediated by 17β estradiol (E2) 15. Oxidative
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stress has been shown to instigate a number of varied responses including cell
proliferation and transformation. Furthermore, an excessive and/or sustained increase in
ROS production has been implicated in the pathogenesis of cancer

16

. Redox balance is

achieved by various enzymatic and non enzymatic antioxidant systems that counteract the
harmful effect of ROS. For example, superoxide dismutase (SOD) catalyses the
dismutation of the superoxide anion into H2O2, while Catalase and glutathione peroxidase
(GPx) metabolize H2O2 into water and molecular oxygen

17, 18

. It is interesting to note

that physiological ROS play a significant role in the regulation of signaling pathways
such as kinase and phosphatase activation/inactivation.

Oxidative stress-induced redox surges could bring about changes in the thiol status of
signaling proteins with alterations in their Phosphorylation/dephosphorylations functions.
These modifications could lead to changes in cellular signaling transduction pathways,
DNA and RNA syntheses, protein syntheses, enzyme activation and cell cycle regulations
19-27

. Signaling proteins such as mitogen-activated protein kinases (MAPK) 27 and protein

tyrosine phosphatases (PTPs) like PTEN (Phosphatase and tensin homolog deleted on
chromosome ten) and CDC25

28

have been shown to be susceptible to oxidation because

they contain essential cysteines which serve as possible targets for ROS in different
pathways 30, 31.

Protein tyrosine phosphatases (PTPs) are important enzymes in cell cycle control and
signal transduction. In conjunction with protein tyrosine kinases (PTKs), PTPs regulate
levels of protein tyrosine phosphorylation in response to cellular signals
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32, 33

. Many

studies have shown that PTKs may be directly activated through the inhibition of PTPs
by ROS 34, 35. For example, PTEN is a redox sensitive phosphatase which has been shown
to be inactivated by ROS. The inactivation of PTEN leads to the sustained phosporylation
and activation of AKT. AKT has been shown to phosphorylate p27 on threonine 157 with
a resultant cytoplasmic sequestration and a consequent inhibition of its nuclear function.

p27 is a Cyclin-kinase inhibitor (CKI) which was originally discovered as a protein
whose expression was induced by different growth inhibitory conditions/agents such as
serum starvation, contact inhibition, transforming growth factor-α or by lovastatin 36. Its
expression is reduced by mitogens like epidermal growth factors and estrogens. Mice
with p27 knockout develop multiorgan hyperplasia and pituitary tumors, thus
underscoring a role for p27 in both proliferation and differentiation

37

. p27 is also well-

known for its ability to inhibit G1 Cyclin/CDK complexes. It is noteworthy that its
activity is regulated by its post-translational modification 38, 39. Hence one may infer that
because of their capacity to oxidize and inactivate PTEN, ROS may be able to regulate
p27 function by modulating its post-translational modification.

We therefore hypothesized that (i) in addition to its known action at the ER, tamoxifen
also prevents estrogen-mediated progression of cell cycle by counteracting estrogeninduced reactive oxygen species signaling, and (ii) as a result of chronic oxidative stress,
and the conversion of estrogen-sensitive breast tumors to a tamoxifen-resistant phenotype
is associated with a progressive shift towards a pro-oxidant environment. Therefore, an
increase in ROS levels promotes the loss of p27 inhibitory function through the
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inactivation of protein tyrosine phosphates (PTPs) and a consequent change in p27
phosphorylation.

To test these hypotheses, we conducted experiments to i) determine the relationship
between tamoxifen and oxidative stress, ii) determine the effect of ROS on p27
expression and its phoshorylation in tamoxifen resistant LCC2 cells, iii) determine if pretreatment of LCC2 cells with biological or chemical antioxidants can restore tamoxifen
sensitivity by re-establishing redox balance within the cells, and iv) determine the effect
of antioxidants on p27 stability and its inhibitory function.

Materials and methods
Materials
Antibodies to p27, Cyclin E, CDK2 and Phosphorylated p27 on Threonine187 were
purchased from Santa Cruz Biotechnology. T157 Phosphorylated p27 antibody was
purchased from Abcam. Beta Actin, 2', 7’-dichlorodihydrofluorescein diacetate (DCFHDA), DMSO, Ebselen and cyclohexamide were purchased from Sigma Aldrich.
Exactacruz immune- precipitation kit was purchased from Santa Cruz Biotechnology.
BrdU kit was purchased from ROCHE. Protein A Agarose was purchased from
Invitrogen. The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT)
were purchased from ViraQuest, Inc. (North Liberty, IA, USA).
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Cell culture
LCC2 cells were provided by Dr Slingerland (Braman Family Breast Cancer Institute,
Miami)). Cells were cultured in DMEM (Gibco) containing 5% Fetal bovine serum
(FBS), 25,000 units of penicillin (base) and 25,000 µg of Streptomycin at 37°C in a fully
humidified atmosphere of 5% CO2 in air. For experiments, 40% Confluent cells were
further cultured in DMEM containing 5% Charcoal Stripped FBS for 24hours to
minimize the effect of serum and synchronize the cells in G1. Synchronized cells were
always treated with 0.01% DMSO, 1uM Tamoxifen (TAM), 100pg E2 or 1uM
fulvestrant.

Adenoviral Transduction
The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT) were
manufactured at ViraQuest, Inc. (North Liberty, IA, USA) by inserting either Ad5
E1/partial E3-deleted replication-deficient adenoviral vector only (EV) or the vector
containing MnSOD (SOD) or Catalase (CAT) gene in the E1 region of the vector.

LCC2 cells were seeded in 100-mm dishes at a density of 1 × 106 cells/dish in the
medium containing charcoal stripped FBS for 24hrs. The medium was then aspirated and
replaced with 5 ml of serum-free medium containing 50pfu of SOD, CAT or EV
adenovirus. After 2 hours of incubation, 10% of charcoal stripped serum was added to the
medium making it 5% charcoal stripped medium. Medium was changed after 24 hours of
adenoviral exposure and treatment(s) were added to pre-designated plates and incubated
for another 48 hours.
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Ebselen Pre-treatment
1x106 LCC2 cells were seeded per 100mm dish in medium with 5% Charcoal stripped
serum. 21 hours post seeding 20μM of Ebselen was added to the culture and incubated
for 3hours. Desired treatments were then added to the culture and incubated for 48 hours.

BrdU Incorporation Assay
For BrdU incorporation, LCC2 cells were seeded in 96-well plates at a density of
2500/well and incubated in 5% CO2 incubator at 37oC. 24 hours after seeding, cells were
either infected with EV, CAT or SOD at a multiplicity of infection (m.o.i) of 50pfu/cell
as described above or pre-treated with 20 μM of Ebselen. After exposure to antioxidants
cells were then stimulated with either 0.01% DMSO, E2 (100pg), TAM (1uM) or E2 +
TAM for 48hours. Following the above treatment, BrdU incorporation assay was carried
out using Cell Proliferation ELISA, BrdU labeling Kit (Roche Molecular Biochemical) in
accordance with manufacturer’s recommendation. Colorimetric changes were acquired at
370 nm with a Tecan Genios microplate reader.

2′, 7′-dichlorofluorescin diacetate (DCFH-DA)
To carry out the DCFH-DA Assay, 10,000/well of LCC2 cells were seeded in a 96-well
plate and cultured in 10% growth medium for 24 hours. After 24 hours growth medium
was aspirated and replaced with serum free medium for another 24 hours after which the
starvation media was aspirated and replaced with 100uL/well of HBSS containing 10 μM
DCFDA pre-diluted with Pluronic F-127 and incubated at 37oC for 20 mins. At the end of
the incubation, DCFH-DA solution was gently aspirated and pre-designated wells were
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then stimulated with 100ul of HBSS containing either 0.01% DMSO (vehicle control), E2
(100pg), TAM (1uM) or E2 + TAM. Cells were further incubated for 5mins after which
fluorescence readings were taken using 485 nm and 535 nm as excitation and emission
filters, at intervals of 5 mins. Optical density readings were obtained using a Tecan
Genios microplate reader.

Western blot
1 x 106 LCC2 cells per 100mm dish were initially exposed to antioxidants as described
above and then stimulated with either 0.01% DMSO, 1μM TAM, or 1μM fulvestrant for
48hours. Post treatment, cells were harvested and lysed in radioimmunoprecipitation
assay (RIPA) buffer [25 mM Tris HCl (pH 7.4), 25 mM NaCl, 1 mM sodium
orthovanadate,10 mM sodium pyrophosphate, 10 mM NaF, 0.5 mM EGTA, 1.0% Triton
X-100, 1 mM PMSF, and 10 mM okadaic acid] for 15 min on ice. Samples were then
briefly sonicated and centrifuged at 10,000 rpm for 10 min at 4°C. The total protein
concentration of the resulting supernatant was determined by Pierce BCA quantification
kit. Equal amount of protein extracts (50 μg) were separated by SDS-PAGE, transferred
to a polyvinylidene difluoride membrane (PVDF), blocked in 1% BSA and fat free milk
solution containing 50 mM NAF for 1hour and blotted with antibodies. Labeled proteins
are visualized with an ECL system (Amersham Biosciences). Band intensity was
determined using densitometric analysis (NIH ImageJ software). The level of p27 was
expressed as its ratio to β-actin.
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For chronic exposure, after exposing cells to antioxidants cells were stimulated with
either DMSO, TAM, or fulvestrant for 21 days after which the cells were harvested for
lysate preparation and Immunoblotting as described above.

Co-immunoprecipitation
For co-immunopreipitation to determine Cyclin E complexes, the Exactacruz protocol
was followed according to the manufacturer’s recommendation. Briefly, after stimulation,
lysate was prepared using ice-cold Nonidet P-40 lysis buffer (0.1% Nonidet P-40, 50 mM
Tris [pH 7.5], 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 0.02 mg each of
aprotinin, leupeptin, and pepstatin per ml). The lysate was then sonicated briefly and
centrifuged at 10,000 rpm for 10 mins. Supernatant was saved and then pre-cleared using
30 μl of Exactacruz pre-clearing matrix for 30minutes at 4oC while rotating. Matrix was
pelleted by microcentrifugation at maximum speed for 30 seconds at 4°C and the
supernatant (cell lysate) was transferred to a new micro centrifuge tube and BCA assay
performed.

IP antibody-IP matrix complex was formed by adding 2 μg of Cyclin E antibody to be
immunoprecipitated to 40 μl of suspended IP matrix and 500 μl PBS and incubating at 4°
C on a rotator overnight. After overnight incubation, matrix was pelleted, supernatant
discarded and pelleted matrix was washed two times with 500 µl of PBS, each time while
repeating the above centrifugation and aspiration steps. After the second wash and microcentrifugation, 300 μg of pre-cleared lysate was added to the IP antibody-IP matrix
complex, and incubated overnight at 4° C after which samples were microcentrifuged at
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maximum speed for 30 seconds at 4° C to pellet IP matrix and the pelleted matrix washed
2-4 times with NP40 lysis buffer and pelleted. After the final wash, 40 µl of 2X reducing
electrophoresis buffer was added to the pellet, boiled for 3 mins, quick-spinned and equal
volumes loaded onto gel, resolved, transferred, and blotted with Cyclin E, Cdk2, and p27
antibodies. Antibody alone, and whole cell lysate controls were run alongside
immunoprecipitates. The same was done for CDK2 and p27. Western blot anti-body was
probed using the appropriate HRP conjugated ExactaCruz reagent.

Soft Agar Colony Formation Assay.
To assess the effect of antioxidants on anchorage-independent cell growth, a soft agar
colony formation assay using either plain or antioxidant pretreated (Ebselen, Catalase or
MnSOD) LCC2 cells was performed. LCC2 cells (1000/well) were suspended in 0.2ml of
charcoal stripped culture

medium containing 0.25% agar and appropriate treatment

(0.01% DMSO or 1μM Tamoxifen or fulvestrant) and poured over a pre-hardened feeder
layer of agarose comprising 0.2 ml of the charcoal stripped medium, containing 0.5%
agar, in a 48 well plate. Cells were fed every 4 days and allowed to incubate for 30 days.
After 14 days of incubation at 37°C in a humidified CO2 incubator, colonies were
counted excluding any colonies with a diameter ≤ 60 μ meter.

P27 protein stability
To determine the effect of antioxidants on p27 stability, 1 x 106 LCC2 cells were seeded
in 100 mm plates in medium with charcoal stripped FBS for 24hours and then some cells
were exposed to either Ebselen or 50 pfu of CAT, SOD or EV. After 24 hours media was
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replaced with fresh medium with charcoal stripped FBS alone for 40 hours. After which
50 μM of cycloheximide was added to media for the indicated period spanning the next 8
hours. Cells were lysed in RIPA buffer for 60 min at 4°C. Samples were then centrifuged
at 10,000g for 10 min at 4°C. The total protein concentration of the resulting supernatant
was determined by BCA quantification. Equal amount of protein extracts (50 μg) were
separated by SDS-PAGE, transferred to a PVDF membrane, blocked in 1% BSA and fat
free milk solution containing 50 mM NAF for 1 hour and blotted with antibodies.
Labeled proteins are visualized with an ECL system (Amersham Biosciences). Band
intensity was determined using densitometric analysis (NIH ImageJ software). The level
of p27kip was expressed as its ratio to β-actin.

Results
Antioxidants mitigate ROS formation in TAM resistant LCC2 cells
To determine the effect of antioxidants on TAM-induced ROS in LCC2 cells, a DCFHDA assay was performed using cells with or without antioxidants. Data reveals that
LCC2 cells generate ROS when exposed to TAM and E2 respectively and the ROS
generated was significantly inhibited by the co-treatment of TAM with E2 (Figs. 1A).
This observation implies that while individual treatment of LCC2 cells with E2 and TAM
are pro-oxidant, TAM possesses an anti-oxidant effect in the presence of E2. Cotreatments of cells with either TAM or E2 and ROS modulators (biological or chemical)
also inhibited TAM-induced ROS (Figs. 1B, C).
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Antioxidants inhibits BrdU incorporation in TAM resistant cells
A BrdU incorporation assay was carried out to determine the effect of antioxidants on
ROS induced DNA synthesis in LCC2 cells. Experimental outcomes show that E2 and
TAM-induced cell proliferation in LCC2 cells is significantly inhibited by the cotreatment of TAM with E2 (Fig. 2A) and by co-treatment of TAM or E2 with Biological
(CAT or SOD) or chemical (Ebselen) ROS modulators (Figs. 2B, C). The ability of ROS
modulators to inhibit TAM or E2 induced DNA synthesis points to the pro-oxidant effect
of TAM or E2 on LCC2 cells and the inherent capacity of this pro-oxidant environment
to promote cell proliferation.

Antioxidants mitigate anchorage independent growth in TAM resistant LCC2 cells.
To determine the effect of antioxidants on anchorage-independent growth in TAM
resistant cells, a colony assay was performed using LCC2 cells. Anchorage independent
growth was significantly inhibited by fulvestrant but not by TAM or DMSO (Fig.3A).
fulvestrant was included in this experiment as a positive control because LCC2 cells are
sensitive to it. Ebselen pretreatment or the over expression of CAT or SOD in TAM
resistant LCC2 cells significantly inhibited anchorage independent growth compared to
EV infected or uninfected cells (Figs. 3B, C). This result further substantiates the prooxidant, growth inducing effect of TAM.

Antioxidants increased p27 expression in TAM resistant cells
Western blotting was carried out to determine the effect of antioxidants on TAM resistant
cells. Fig. 4A reveals that the treatment of LCC2 cells with fulvestrant significantly
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increased p27 expression compared to TAM. Ebselen pretreatment or the over expression
of CAT or SOD in LCC2 cells also resulted in a significant increase in p27 expression
when treated with TAM compared to EV infected cells and uninfected cells (Fig.4B, C).
This is similar to the effect observed following exposure to fulvestrant in Fig.4A. It may
thus be inferred that the TAM induced pro-oxidant environment may promote LCC2 cell
proliferation by decreasing p27 expression.

Antioxidants decreased p27 phosphorylation in TAM resistant cells
Western blotting was also carried out to determine the effect of antioxidants on p27
phosphorylation. Panel I. Results obtained from this experiment show that treatment of
uninfected LCC2 cells with fulvestrant resulted in significantly reduced phosphorylation
of p27 on Threonine 157(T157) relative to TAM treated cells which showed a
phosphorylation level that was ≥ T157 phosphorylation in cells exposed to DMSO
control (Fig.5A). Over expression of CAT or SOD or Ebselen pretreatment in LCC2 cells
leads to a significant decrease in T157 phosphorylation when treated with TAM
compared to either EV infected control or uninfected cells. (Figs.5B, C). Once again the
cells exposed to ROS modulators acted like those exposed to fulvestrant by showing a
decrease in p27 phosphorylation on T157 unlike the unexposed cells which showed an
increase in T157 phosphorylation. It is noteworthy that phosphorylation of p27 on T157
results in increased cytoplasmic sequestration of p27 and vice versa.

Panel II. In Fig.5A Experimental outcome reveals a significant reduction of p27
phosphorylation on Threonine 187 (T187) in LCC2 cells exposed to fulvestrant compared
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to TAM. (B) LCC2 cells over expressing CAT or SOD or pretreated with Ebselen also
shows a significant reduction in the level of p27 phosphorylation on T187 when treated
with TAM compared to either EV control or uninfected cells.
A result similar to the one obtained for T157.

Prolonged exposure of LCC2 cells to antioxidants and TAM treatment increased
p27 expression
Immunoblotting was carried out to determine the effect of chronic antioxidant and TAM
exposure on p27 expression. Results obtained show that prolonged (21 days) exposure of
LCC2 cells to fulvestrant significantly increased p27 expression compared to TAM (Fig.
6A). Over expression of CAT or SOD in LCC2 cells also resulted in a significant
increase in p27 expression when treated with TAM compared to EV infected cells and
uninfected cells (Fig.6B). This shows that chronic exposure to antioxidants and TAM
have the same outcome as short term (48hrs) exposure.

Prolonged exposure of LCC2 cells to antioxidants and TAM treatment reduced p27
phosphorylation
The following are results from Immunoblotting to determine the effect of antioxidants on
p27 phosphorylation. Panel I. Chronic treatment of uninfected LCC2 cells with
fulvestrant resulted in a significant reduction in the phosphorylation of p27 on Threonine
157(T157) compared to TAM treated cells which showed an increase in the level of p27
phosphorylation on T157(Fig.7A). Treatment of LCC2 cells over expressing CAT or
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SOD also resulted in a reduction in phosphorylation when compared to either EV control
or uninfected cells exposed TAM (Fig.7B).

Panel II. Fig.8A shows that chronic exposure of LCC2 cells to fulvestrant resulted in a
significant reduction in the level of p27 phosphorylation on Threonine 187 (T187)
compared to TAM. LCC2 cells over expressing CAT or SOD upon treatment with TAM
showed a significant reduction in phosphorylation when compared to either EV control or
uninfected cells exposed to TAM.

Antioxidants increased p27 binding to CylinE and CDK2 in TAM resistant cells
To determine the effect of Antioxidants on p27 binding to CDK2 and or CyclinE a coimmunoprecipitation was performed. Treatment of LCC2 cells with fulvestrant resulted
in an increase in p27 binding to CDK2 and CyclinE compared to TAM treatment (Fig.
8A). Ebselen pretreatment or the Over expression of CAT or SOD in LCC2 also resulted
in increased binding of p27 to CDK2 and CyclinE when treated with TAM compared to
either EV infected controls or uninfected cells exposed to TAM (Fig.8B, C).

Antioxidants increased CDK2 binding to P27 and CyclinE in TAM resistant cells To
determine the effect of Antioxidants on p27 binding to CDK2 and or CyclinE a coimmunoprecipitation was performed. Treatment of LCC2 cells with fulvestrant resulted
in an increase in CDK2 binding to p27 and CyclinE compared to TAM treatment (Fig.
9A). Ebselen pretreatment or the Over expression of CAT or SOD in LCC2 also resulted

95

in increased binding of CDK2 to p27 and CyclinE when treated with TAM compared to
either EV infected controls or uninfected cells exposed to TAM (Fig.9B, C).

Antioxidant Increased CylinE binding to CDK2 and p27 in TAM resistant cells
To determine the effect of antioxidants on CyclinE binding to CDK2 and or p27 a coimmunoprecipitation was performed. In (Fig. 10A), treatment of LCC2 cells with
fulvestrant resulted in an increase in CyclinE binding to CDK2 and p27 compared to
TAM while data from (Fig.10B, C) also showed increased CyclinE binding to CDK2 and
p27 in LCC2 cells over expressing CAT or SOD compared to either EV infected cells or
uninfected cells exposed to TAM.

P27 expression is less in LCC2 cells compared to MCF7 when synchronized
Pursuant to the finding in Figures 4 and 5 Immunoblotting was performed to compare the
levels of p27 in TAM resistant LCC2 cells to its parent MCF7 cells. Results obtained
showed the level of p27 expression in LCC2 to be about 40% less than that in MCF7
cells of equal protein concentration, exposed to the same experimental conditions.

Antioxidants Increased p27 stability in TAM resistant cells
To determine p27 stability a stability assay was performed using cycloheximide. LCC2
cells not pre-exposed to antioxidants had a shorter half life (2.42hours) compared to CAT
or SOD over expressing cells.
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Discussion
In this study, we hypothesized that, (i) In addition to its known action at the ER, TAM
also prevents estrogen-mediated progression of cell cycle by counteracting estrogeninduced ROS signaling, and (ii) As a result of chronic oxidative stress, the conversion of
estrogen-sensitive breast tumors to a Tamoxifen-resistant phenotype is associated with a
progressive shift towards a pro-oxidant environment. We therefore propose that an
increase in ROS levels promotes the loss of p27 inhibitory function through the
inactivation of protein tyrosine phosphates (PTPs) and a consequent change in p27
phosphorylation.

TAM, a known selective estrogen receptor modulator (SERM), has been widely shown to
possess either pro- or antioxidant properties

7-13

. Our results show that TAM possesses

the capacity to act like both an oxidant and an antioxidant. Exposure of LCC2 cells to
TAM or E2 induced the formation of reactive oxidants (Fig.1A). These reactive oxidants
were then inhibited by the co-treatment of E2 with TAM, much like the ROS inhibition
observed in cells pre-treated with antioxidants (Figs.1B & C). We further demonstrated
that E2 and TAM induced ROS in LCC2 cells were capable of inducing cell proliferation
which was then inhibited by pre-exposure of the cells to biological or chemical
antioxidants or the co-treatment of TAM with E2 (see Figs.2 & 3). These findings make a
case for the dual role of TAM as both a pro- and an antioxidant. Based on these results, it
appears that the antioxidant effect of TAM is observed in the presence of E2.
Exposure of TAM resistant LCC2 cells to TAM resulted in a decrease in p27 expression
in contrast to the increase in p27 expression observed when the same cells were treated
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with fulvestrant (see Fig.4A). Fulvestrant is an anti-estrogen to which LCC2 cells are
known to be sensitive. We also observed that the exposure of these cells to TAM
increased p27 phosphorylation on T157 and T187 while exposure to fulvestrant appeared
to have the opposite effect (Fig5. Panels 1& IIA).

Conversely, following the antioxidant pre-treatment/over expression, a fulvestrant-like
effect i.e., an increase in p27 expression (see Figs. 4B &C) and a decrease in p27
phosphorylation on T157 and T187 was observed in TAM treated cells compared to cells
which were not pre-exposed to antioxidants (Figs. 5 Panels I & II B & C). It can thus be
inferred that the over expression of antioxidant in LCC2 cells leads to an increase in p27
expression and a decrease in its phosphorylation on T157 and T187. This is in line with
other previous studies

40 - 42

, which showed that treatment with anti-estrogen drugs like

TAM or fulvestrant caused cell cycle arrest, with up-regulation of p21 and p27 levels, an
increase in their binding to Cyclin E–Cdk2, and kinase inhibition 40. Additionally, results
from our comparison of p27 expression between Tamoxifen sensitive parental MCF7 and
Tamoxifen resistant LCC2 cells showed a 40% decrease in p27 expression in LCC2 cells
compared to MCF7 (Fig.11). This implies that TAM resistance could be associated with a
decrease in p27 expression rather than the loss p27 function in which case, an increase in
p27 expression following antioxidant pre-treatment is a significant finding.

Though the observed experimental outcomes imitate the effect of fulvestrant on LCC2
cells, we cannot yet interpret this to either denote an increase in TAM sensitivity or the
growth inhibitory function of p27. This is because previous studies have indicated that
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p27 potentially has dual role(s) in tumor – suppression and promotion 43-46 depending on
its subcellular redistribution and its binding to the Cyclin-Cdk complex. The binding of
p27 to the Cyclin E/Cdk2 complex in the nucleus promotes its function as a CKI while
cytoplasmic sequestration takes it away from its nuclear Cyclin/Cdk target to the growth
promoting interaction with Cyclin D/Cdk4/6 complex 47.

In line with previous studies

40

, we also found an increase in the binding of Cyclin E–

Cdk2 and p27 in TAM treated cells over expressing antioxidant (CAT and SOD)
compared to control cells not exposed to antioxidants (see Figs. 8, 9 & 10). In the context
of our initial finding of increased p27 expression and decreased phosphorylation, these
results of increased binding of p27 to Cyclin E–Cdk2 and increased p27 stability in cells
over expressing antioxidants (Fig. 12), are highly suggestive of an increase in the TAM
sensitivity, most likely due to p27 inhibitory function in antioxidant over expressing
LCC2 cells.

In summary, we demonstrate that TAM has the capacity to induce ROS formation and act
as an antioxidant in the presence of E2. Following prolonged exposure to TAM and an
increasingly pro-oxidant environment, the oxidants formed are able to promote cell
proliferation. This could be by decreasing p27 expression and regulation of its activity by
post-translational modification involving an increase in p27 phosphorylation on T157 and
T187. This is accompanied by a resultant cytoplasmic sequestration, decreased binding to
Cyclin E/Cdk2 complex and loss of p27 stability resulting in the loss of sensitivity to
TAM. Clearly, these events are oxidant driven, therefore they can be reversed by
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antioxidant over expression or pre-treatment, with a resultant growth inhibitory effect and
increased TAM sensitivity.
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Figures and Legend
Fig 1-LCC2.

Antioxidants mitigate ROS formation in TAM resistant LCC2 cells. To determine the
effect of antioxidants on TAM induced ROS in LCC2 cells, 1 x104cells/well were seeded
in a 96-well plate overnight and serum starved for 24 hrs. Post-starvation 100 μL/well of
HBSS containing 10 μM DCFH-DA pre-diluted with Pluronic F-127 was added to each
well and incubated at 37oC for 20 mins. DCFH-DA solution was then aspirated and
replaced with 100 μL of HBSS containing the desired treatments. Cells were further
incubated for 5 mins and fluorescence readings were taken using 485 nm and 535 nm as
excitation and emission filters, at intervals of 5mins. A) LCC2 cells treated with TAM,
E2 or TAM/E2; B) TAM resistant cells over expressing Catalase (CAT) and MnSOD
(SOD) were treated with TAM, E2 or TAM/E2; C) LCC2 cells co-treated with Ebselen
and TAM, E2 or TAM/E2. Assay was performed 3x and data is expressed as mean
percentage change from control +/- SE, (p 0.05). (*) denotes significance when treatment
is compared to DMSO control, (**) indicates significance when compared to EV/DMSO

104

control while (***) indicates significance when treatment is compared to DMSO and
each individual treatment.

Fig 2-LCC2

Antioxidants inhibit BrdU incorporation in TAM resistant cells. To determine the
effect of antioxidants on ROS induced DNA synthesis in LCC2 cells, 2.5 x 103 cells/well
were seeded in a 96-well plate overnight and exposed to chemical or biological
antioxidants as described in methods. After exposure to antioxidants, cells were then
stimulated with E2, TAM or fulvestrant for 46 hrs and pulsed labeled with BrdU for 2
hrs. BrdU assay was then carried out as recommended by manufacturer. Colorimetric
changes were acquired at 370 nm with a Tecan Genios microplate reader at 5 mins
interval. A) LCC2 cells treated with TAM, E2 or TAM/E2; B) TAM resistant cells over
expressing CAT and SOD and treated with TAM, E2 or TAM/E2; C) LCC2 cells cotreated with Ebselen and TAM, E2 or TAM/E2. Assay was performed 3x and data is
expressed as mean percentage change from control +/- SE, (p 0.05). (*) denotes
significance when treatment is compared to DMSO control, (**) indicates significance
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when compared to EV/DMSO control while (***) indicates significance when treatment
is compared to DMSO and each individual treatment.

Fig 3-LCC2

Antioxidants mitigate anchorage independent growth in TAM resistant LCC2 cells.
To determine the effect of antioxidants on anchorage-independent growth in TAM
resistant cells, LCC2 cells were incubated on soft agar with or without antioxidants
exposure for 21 days and colonies ≥60 microns in diameter were enumerated. A)
Anchorage independent growth of TAM resistant cells; B) LCC2 cells over expressing
Catalase (CAT) or MnSOD (SOD); C) LCC2 cells pretreated with chemical antioxidant.
Assay performed 3x and data is expressed as mean percentage change from control +/SE, (p 0.05). (*) denote significance when treatment is compared to DMSO control
while (**) indicates significance when compared to EV/DMSO control.
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Fig 4-LCC2

Antioxidants Increased p27 expression in TAM Resistant cells. LCC2 cells were
exposed to antioxidants as described in methods and treated with TAM and fulvestrant
respectively. After 48 hrs incubations, cells were harvested with lysis buffer and 50 ug
whole cell lysate (WCL) were fractionated on 12% SDS-PAGE gel. Immunoblots were
probed with p27 or β actin antibodies respectively. A) LCC2 cells treated with TAM or
fulvestrant, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv. Assay was
performed 3x. P27 protein level was determined by densitometric analysis and expressed
as the percentage mean of its ratio with β actin relative to control +/- SE, (p 0.05). (*)
denotes significance when treatment is compared to DMSO control while (**) indicates
significance when compared to EV/DMSO control.

107

Fig 5-LCC2

Antioxidants decreased p27 phosphorylation in TAM Resistant cells. (Panel I) A)
LCC2 cells treated with TAM or Fulv and probed with p27 or p27 phosphorylated on
Threonine 157 (T157); B) LCC2 cells over expressing CAT or SOD were treated with
TAM and Fulv, then probed with p27 or T157; C) LCC2 cells co-treated with chemical
antioxidant and TAM or Fulv, then probed with p27 or T157. (Panel 2) A) LCC2 cells
treated with TAM or Fulv and probed with p27 or p27 phosphorylated on Threonine 187
(T187); B) LCC2 cells over expressing CAT or SOD were treated with TAM and Fulv,
then probed with p27 or T187; C) LCC2 cells co-treated with chemical antioxidant and
TAM or Fulv, then probed with p27 or T187. Assay was performed 3x. Phosphorylated
p27 levels were determined by densitometric analysis and expressed as the percentage
mean of their ratios to the ratio of p27 with β actin relative to control +/- SE, (p 0.05). (*)
is denotes significance when compared to DMSO control while (**) indicates
significance when compared to EV/DMSO control.
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Fig. 6-LCC2

Prolonged antioxidant treatments increased p27 expression in LCC2 cells. LCC2
cells over expressing CAT or SOD were exposed to either TAM or Fulv for 21 days. A)
Uninfected cells were treated with TAM or Fulv and probed for p27 and actin; B) CAT or
SOD infected cells treated with TAM or Fulv and probed for p27 and β actin. Assay was
performed 3x. P27 protein level was determined by densitometric analysis and expressed
as the percentage mean of its ratio with β actin relative to control +/- SE, (p 0.05). (*)
denotes significance when treatment is compared to DMSO control while (**) indicates
significance when compared to EV/DMSO control.
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Fig 7-LCC2

Prolonged exposure of LCC2 cells to Antioxidants decreased p27 phosphorylation in
LCC2. (Panel I) A) LCC2 cells treated with TAM or Fulv for 21 days and probed with
p27 or T157; B) LCC2 cells over expressing CAT or SOD were treated with TAM and
Fulv for 21 days, and then probed with p27 or T157. (Panel II) A) LCC2 cells treated
with TAM or Fulv for 21 days and probed with p27 or T187; B) LCC2 cells over
expressing CAT or SOD were treated with TAM and Fulv for 21 days, and then probed
with p27 or T187. Assay was performed 3x. Phosphorylated p27 levels were determined
by densitometric analysis and expressed as the percentage mean of their ratios to the ratio
of p27 with β actin relative to control +/- SE, (p 0.05). (*) denotes significance when
compared to DMSO control while (**) indicates significance when compared to
EV/DMSO control.
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Fig 8-LCC2.

Antioxidant Increased p27 binding to CylinE and CDK2 in TAM resistant cells.
LCC2 were exposed to antioxidants as described in methods and treated with TAM and
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer
and 350 ug WCL was immunoprecipitated (IP) with p27 antibody using Exactacruz kit as
recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblots were
probed with p27, CDK2 or CyclinE antibodies respectively. A) LCC2 cells treated with
TAM or Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv.
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Fig 9- LCC2

Antioxidants Increased CDK2 binding to CylinE and p27 in TAM resistant cells.
LCC2 were exposed to antioxidants as described in methods and treated with TAM and
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer
and 350 ug WCL was immunoprecipitated (IP) with CDK2 antibody using Exactacruz kit
as recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblot were
probed with, CDK2, p27 or CyclinE antibodies. A) LCC2 cells treated with TAM or
Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and Fulv, C)
LCC2 cells co-treated with chemical antioxidant and TAM or Fulv.
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Fig10-LCC2

Antioxidant Increased CylinE binding to CDK2 and p27 in TAM resistant cells.
LCC2 were exposed to antioxidants as described in methods and treated with TAM and
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer
and 350 ug WCL was immunoprecipitated (IP) with CDK2 antibody using Exactacruz kit
as recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblots were
probed with, CyclinE, p27 or CDK2, antibodies respectively. A) LCC2 cells treated with
TAM or Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv.
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Fig11-LCC2

P27 expression is less in LCC2 cells compared to MCF7. 1million LCC2 and MCF7
cells were seed and serum starved for 48 hours after which cells were harvested with lysis
buffer and 50 ug whole cell lysate (WCL) were fractionated on 12% SDS-PAGE gel.
Immunoblot were probed with p27 or beta actin antibodies respectively. Figure shows
p27 and Actin expression in LCC2 and MCF7 cells. Assay was performed 3x. P27
protein level was determined by densitometric analysis and expressed as the percentage
mean of its ratio with β actin relative to control +/- SE, (p 0.05 (*) is indicates
significance when p27 expression in LCC2 cells is compared to that of MCF7 cells.
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Fig12-LCC2

Antioxidants increased p27 stability. Uninfected LCC2 cells (A) and LCC2 cells over
expressing CAT(B), SOD(C) or EV(D) were treated with 50uM cycloheximide (CHX)
for the time periods indicated, and p27 protein levels were determined by
immunoblotting and densitometry with β actin as internal control.

IV

ESTROGEN INDUCED ROS MEDIATES IN VITRO CELL

PROLIFERATION AND GROWTH THROUGH PTEN OXIDATION AND AKTNRF-1 PHOSPHORYLATION

Abstract
Tamoxifen resistance is still a significant problem in the treatment of estrogen receptor
positive breast cancer. Due to de novo resistance, only about 70% of breast cancer
patients will initially respond to tamoxifen treatment. About 40% of patients who were
initially responsive to the drug and majority of the patients with metastatic breast disease
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will develop an acquired resistance to the drug over time. Although there has been an
improvement in our understanding of the subject, the molecular mechanism(s) that result
in the evolution of tamoxifen resistant breast cancer is still unclear. In this study we
explored the role of reactive oxygen species (ROS) in the advancement of breast cancer
from a tamoxifen-sensitive to a tamoxifen-resistant phenotype. ROS are products of
cellular metabolism and an excessive and/or sustained increase in their production has
been implicated in the pathogenesis of cancer. Furthermore, ROS induces oxidative stress
which has been shown to initiate various cellular responses including alteration of
intracellular redox state and the oxidative modification of certain signaling proteins
resulting in the post translational modification of their downstream targets. Interestingly,
tamoxifen like estrogen, has been shown to induce ROS formation, making it probable
that tamoxifen induced ROS generated as a result of prolong tamoxifen treatment of
breast cancer patients may play a critical role in the development of its resistance. Using
MCF7 breast cancer cells and standard laboratory techniques, we explored the role of
ROS and redox signaling in development of tamoxifen resistance in breast cancer cells.
We were interested in finding out how and if ROS, through the oxidation of Phosphatase
and tensin homolog (PTEN) induces the phosphorylation and activation of nuclear
respiratory factor 1(NRF-1) resulting in its binding to the promoter region of certain cell
cycle genes, thereby promoting cell proliferation and a transformation of the cells to a
resistant phenotype. We also wanted to find out if this process can be reversed by preexposing the cells to biological or chemical antioxidants. Our finding was that,
tamoxifen-induced ROS oxidizes PTEN resulting to the hyper-stimulation of the
Akt/PI3K pathway and a consequent NRF-1phophorylation/activation. Activated NRF-1
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then binds to the promoter region of some cell cycle genes inducing cell proliferation. We
also found that pre-treating the cell with anti-oxidants restored sensitivity to tamoxifen.

Introduction
PTEN (phosphatase and tensin homologue deleted from chromosome 10) is a redox
sensitive dual specificity phosphatase 1. It is a known tumor suppressor because of its
ability to regulate the cell cycle either by preventing cells from dividing too fast or
dividing in an uncontrolled manner 2 such as that seen in cancer cells. The protein which
is a negative-regulator of the phosphatidylinositol 3-Kinase (PI3K)/Akt pathway acts by
dephosphorylating

phosphatidyl-inositol3,4,5-trisphosphate (PI(3,4,5)P3) at the 3’

position of the inositol ring, thereby counteracting the effect of PI3K and inactivating this
key player in the survival pathway 3.

The tumor suppressor aspect of PTEN function is pertinent in the context of human
disease since a number of studies have found PTEN deficiency, which could arise either
by polymorphic mutation or gene deletion, to be a cause of cancer 4, 5. Indeed one of the
reasons for the activation of Akt signaling in cancers is the mutation or inactivation of
PTEN 6. However, PTEN inactivation and the resulting PI3K/Akt pathway hyperactivation could occur through mechanisms other than those that target the integrity of
the gene 7.

Alternate mechanisms of the down regulation of PTEN activity by posttranslational
modifications such as phosphorylation and oxidation, though not directly implicated in
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cancer, have been documented

8-11

. Furthermore, reactive oxygen species (ROS) have

been shown to oxidize PTEN at its active site ensuing in the formation of a disulphide
bond and a subsequent PTEN inactivation. Several studies have demonstrated the ability
of reactive oxygen species to reversibly oxidize PTEN and other dual specificity
phosphatases, leading to their temporary inactivation

12 -13

. Indeed a number of studies

have looked into the temporary inactivation of PTEN by ROS and its effect on
downstream molecules like Akt and its substrates. For example Connor et al and others
have shown that PTEN oxidation enables PtdIns(3,4,5)P3 to directly activate Akt, which
in turn activates p70 S6 kinase and inhibits the Akt substrate, glycogen synthase kinase-3
thereby regulating cellular metabolism and the cell cycle 13,14.

A less well known Akt substrate is NFF1 (nuclear respiratory factor-1/α-palindromebinding protein)

15

which is a redox sensitive transcription factor

to regulate metabolism and cell proliferation

17-20

16

that has been shown

. A study by Piatandosi and Suliman

(2006), has demonstrated how stimulation of PI3K by exogenous oxidants activate Akt
and promotes NRF1 phosphorylation and nuclear translocation

15

. Additionally, it has

been shown that exposure of breast cancer cells to estrogen (E2) induces cell growth

21

and an increase in NRF1 expression 22. Since estrogen has been shown to promote ROS
formation 23, we considered it pertinent to examine a hitherto unexplored possibility that
E2-induced ROS could result in PTEN inactivation, a consequent increase in NRF1
expression and phosphorylation and an effect on the cell cycle. In the event of this
concept being cogent, we also wanted to determine the effect of antioxidants on our
proposed pathway.
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In this study, we show how estrogen induced PTEN oxidation in MCF7 results in the
hyper-activation of the PI3K/Akt signaling pathway with a consequent increase in the
expression and phosphorylation of NRF1 and a resultant binding of NRF1 to the
promoter region of cell cycle genes. We also show how pre-exposing MCF7 cells to
antioxidants is able to reverse the PTEN oxidation and its downstream effects.

Materials and methods
Cell culture and Materials
MCF7 cells were obtained from Gainsville. Cells were cultured in DMEM (Gibco)
containing 10% fetal bovine serum, 25,000 units of penicillin (base) and 25,000 µg of
Streptomycin at 37°C in a fully humidified atmosphere of 5% CO2 in air. For
experiments, 70% Confluent cells were further cultured in serum free DMEM to
minimize the effect of serum and synchronize the cells in G0. Synchronized cells were
always stimulated with 0.01% DMSO or 100pg E2.

Antibodies to NRF1 was obtained from Rockland, PTEN was obtained from cell
signaling while p27, AKT and PAKT ser 473 were purchased from Santa Cruz
biotechnology. T157 Phosphorylated p27 antibody was purchased from Abcam. Beta
Actin, 2', 7’-dichlorodihydrofluorescein diacetate (DCFH-DA), DMSO and Ebselen were
purchased from Sigma Aldrich.

BrdU kit was purchased from ROCHE. Protein A

Agarose was purchased from Invitrogen. The adenoviruses AdEmpty (EV), AdMnSOD
(SOD), and AdCatalase (CAT) were manufactured at ViraQuest, Inc. (North Liberty, IA,
USA). Primers for CyclinB1, CDC2, CDC25C, PRC1and PCNA where purchased from
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Applied Biosystems. The Upstate kit for ChIP assay was purchased from upstate
biotechnology.

Adenoviral Transduction
The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT) were
manufactured at ViraQuest, Inc. (North Liberty, IA, USA) by inserting either nothing
(EV) or the MnSOD or Catalase gene into the E1 region of an Ad5 E1/partial E3-deleted
replication-deficient adenoviral vector.

MCF7 cells were plated in 100-mm dishes at a density of 1 × 106 cells/dish in charcoal
stripped medium. The following day, the medium was aspirated and replaced with 5 ml
of serum-free medium containing 200pfu of SOD, CAT or EV adenovirus for 24hours
after which cells were stimulated with required treatments for the desired amount of time.

Ebselen Pre-treatment
1million MCF7 cells were plated per 100mm dish in 10% serum medium. 21hours post
seeding 20uM of Ebselen was added to the medium for 3hours after which cells were
stimulated with the desired treatments for 24 hours.
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BrdU Incorporation Assay
For BrdU incorporation, MCF7 cells were seeded in 96-well plates at a density of
2500/well and incubated in 5% CO2 incubator at 37oC. 24 hours after seeding, cells were
either infected with AdCatalase, AdMnSOD or AdEV at a multiplicity of infection
(m.o.i) of 290pfu/cell as described above or pre-treated with 40uM of Ebselen. After
exposure to antioxidants cells were then stimulated with either 0.01% DMSO or E2
(100pg) for 24hours. After stimulation, BrdU incorporation was carried out using Roche
Bioscience (Cell Proliferation ELISA, BrdU Kit; Roche Molecular Biochemical,
Indianapolis, IN) labeling kit in accordance with manufacturer’s recommendation.
Colorimetric changes acquired at 370 nm with a Tecan Genios microplate reader.

2′, 7′-dichlorofluorescin diacetate (DCFH-DA)
To carry out the DCFH-DA Assay, 10,000/well of MCF7 cells were seeded in a 96-well
plate and cultured in 10% growth medium for 24hours. After 24hours growth medium
was aspirated and replaced with starvation medium for another 24hours after which the
starvation media was aspirated and replaced with 100uL/well of HBSS containing 10uM
DCFDA pre-diluted with Pluronic F-127 and incubated at 37oC for 20mins. At the end of
the incubation, DCFH-DA solution was gently aspirated and pre-designated wells were
then stimulated with 100ul of HBSS containing either 0.01% DMSO (vehicle control) or
E2 (100pg). Cells were further incubated for 5mins after which fluorescence readings
were taken using 485 nm and 535 nm as excitation and emission filters, at intervals of
5mins. Optical density readings were obtained using a Tecan Genios microplate reader.
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Westernblot
1 million MCF7 cells per 100mm dish were initially exposed to antioxidants as described
above and then stimulated with either 0.01% DMSO, or E2 30mins. Post treatment, cells
were harvested and lysed in radioimmunoprecipitation assay buffer [25 mM Tris HCl (pH
7.4), 25 mM NaCl, 1 mM sodium orthovanadate,10 mM sodium pyrophosphate, 10 mM
NaF, 0.5 mM EGTA, 1.0% Triton X-100, 1 mM PMSF, and 10 mM okadaic acid] for 15
min on ice. Samples were then briefly sonicated and centrifuged at 10,000rpm for 10 min
at 4°C. The total protein concentration of the resulting supernatant was determined by
BCA quantification. Equal amount of protein extracts (50ug) were separated by SDSPAGE, transferred to a polyvinylidene difluoride membrane, blocked in 1% BSA and fat
free milk solution containing 50mM NAF for 1hour and blotted with antibodies. Labeled
proteins are visualized with an ECL system (Amersham Biosciences). Band intensity was
determined using densitometric analysis (NIH ImageJ software). The level of protein
level was expressed as its ratio to βactin.

Soft Agar Colony Formation Assay.
To assess the effect of antioxidants on anchorage-independent cell growth, a soft agar
colony formation assay using either plain or Ebselen pretreated MCF7 cells was
performed. MCF7 cells (1000/well) were suspended in 0.2ml of charcoal stripped culture
medium containing 0.25% agar and appropriate treatment (0.01%DMSO, 100pg E2,
1uM Tamoxifen, or co-treatment of TAM with E2 ) and poured over a pre-hardened
feeder layer of agarose comprising 0.2 ml of the charcoal stripped medium, containing
0.5% agar, in a 48 well plate. Cells were fed every 4 days and allowed to incubate for
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30days. After 14 days of incubation at 37°C in a humidified CO2 incubator, colonies
counted excluding any colonies with a diameter ≤ 60.

Identification of Reduced and Oxidized Forms of PTEN by Immunoblot Analysis.
After stimulation, I million/100mm dish of MCF7 cells in 1 ml of HBSS were scraped
into 0.2 ml of ice-cold 50% trichloroacetic acid and transferred to microfuge tubes. The
cell suspensions were sonicated briefly and then centrifuged at 2000g for 5 min. The
supernatants were removed, and the pellets were washed with acetone and then
solubilized in 0.2 ml of 100 mM Tris-HCl (pH 6.8) buffer containing 2% SDS and 40
mM NEM. 5ul of the solubilized pellets were subjected to SDS-PAGE under
nonreducing conditions, and the separated proteins were transferred electrophoretically to
a polyvinylidene difluoride membrane.

The membrane was then subjected to immunoblot analysis with either rabbit antibodies to
PTEN or
horseradish

monoclonal antibody to Beta Actin. Immune complexes were detected with
peroxidase-conjugated

secondary

antibodies

and

enhanced

chemiluminescence reagents (Amersham Biosciences). The intensity of PTEN bands was
quantitated with NIH ImageJ.

Chromatin Immunoprecipitation (ChIP) Assay

This assay was carried out using the upstate protocol that came with the kit. Briefly, after
stimulation, protein complex was cross-linked to DNA by adding formaldehyde directly
to culture medium to a final concentration of 1% and incubate for 10 minutes at 37C.
Cells were washed twice with ice cold PBS containing protease inhibitors scraped into
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conical tube and Pelleted for 4 minutes at 2000 rpm at 4ºC. Cell pellet was then lysed in
SDS Lysis buffer for 10 minutes on ice. Lysate was sonicated (5 x 15pulses) and
centrifuged for 10 minutes at 13,000 rpm at 4°C. 150 ul of the sonicated cell pellet
suspension was transferred to a new 1.5 ml eppendorf tube and diluted 10times in ChIP
Dilution buffer containing protease inhibitors.

1% (~15 ul) was kept aside as

input/starting material. 1.5 ml diluted cell pellet suspension was pre-cleared with 60 ul of
Salmon Sperm DNA/Protein A Agarose-50% slurry for 2 hours at 4ºC with agitation.
Agarose was pelleted by brief centrfugation (1min @ 1000rpm). The supernatant fraction
was collected and the immunoprecipitating antibody added to the 1.5 ml supernatant
fraction and incubate overnight at 4ºC with rotation. A non-specific antibody for
immunoprecipitation as negative control. 40 ul of Salmon Sperm DNA/Protein A
Agarose Slurry was added for another two hour at 4ºC with rotation to collect the
antibody/protein complex. Agarose was then pelleted, supernatant was discarded and
washed with different wash buffers for 3-5minutes per wash. The histone complex was
then eluted from the antibody and all samples including the input were reverse crosslinked by heating at 65ºC for 6 hours. DNA was then recovered by ethanol precipitation
and PCR analysis performed.

Immunofluorescence Labeling
Cells were seeded (1.0x104 cells/chamber) and stimulated in chamber slides as indicated
in the legends of the figures. After treatment, cells were fixed with ice cold methanol for
15mins, and permeabilized with 0.5% Triton X-100 for 30min. Then the cells were
blocked with 1% normal goat sera for 1 hr after which they were probed simultaneously
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with antibodies diluted 1: 500 for NRF1; or 1:1500 for phosphor serine. Alexa Fluor
labeled secondary antibodies directed against primary antibodies was diluted 1:1000. The
confocal fluorescence images were scanned on a Nikon TE2000U inverted fluorescence
microscope equipped with a Nikon D-Eclipse C1 laser scanning confocal microscope
system (Nikon Corp., USA). The z-series scanning were done at every 1 μm up to a zdepth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2 Plan Fluor oil immersion
objective. The built-in Nikon EZ-C1 software was used for confocal image acquisition
and analyses.

Results
Estrogen induces ROS in MCF-7. To determine whether E2 induces ROS in breast
cancer cells, MCF-7 cells were treated with either E2 or E2 with ROS modulators as
described in methods. Results showed that cells exposed to E2 induced ROS formations
(Fig.1A). However, co-treatment of cells with E2 and ROS modulators (CAT or Eb)
inhibited estrogen’s ability to induce ROS formations (Fig.1B).

Estrogen induced ROS mediates in vitro proliferation and growth of MCF-7 cells.
To ascertain whether E2 induced ROS facilitates in vitro proliferation and growth of
breast cancer cells, MCF-7 cells were seeded for BrdU and soft agar assay as described in
methods. Cells were subsequently treated with E2 or E2 and ROS modulators. BrdU
incorporation, which is a marker of cells proliferation and soft agar colony formation,
which is a hallmark of anchorage independent cancer growth, were analyzed and
enumerated as described in methods and legends. Data indicate that E2 induced
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proliferation of MCF-7 cells were abrogated by ROS modulators (Fig 2). Similarly, E2
induced anchorage independent growth of breast cancer cells were abolished by ROS
modulators (Fig 3). These findings indicate that estrogen induced proliferation and
growth of breast cancer cells are redox dependent.

Estrogen induced ROS oxidizes PTEN in MCF-7 cells. Oxidation of PTEN by ROS
has been demonstrated to promote carcinogenesis and growth of cancer cells (PMID:
15534200). We investigated whether E2 induced ROS also oxidizes PTEN thereby
promoting E2 induced proliferation and growth of breast cancer cells. Western blot
analysis indicates that while H2O2 are potent oxidizers of PTEN (Fig. 4), E2 induced
ROS can similarly oxidize PTEN albeit to a lesser extent compared to H2O2 (Fig. 5A).
However, when cells were co-treated with either Catalase or Ebselen, E2 induced PTEN
oxidation were significantly reversed (Figs. 5B & C). These findings indicates that E2
induced ROS can lead to PTEN oxidation which could alter downstream signaling
process that favors breast cancer proliferation and growth in response to estrogens.

Estrogen induced PTEN oxidation activates Akt phosphorylation in MCF7 cells.
Western blot analysis were carried out to determine whether E2 induced PTEN oxidation
would lead to increased Akt activation and whether ROS modulators would attenuate Akt
activation in E2 treated breast cancer cell. Our study showed that E2 induced significant
Akt phosphorylation compared to vehicle treated cells (Fig. 6A). When cells were cotreated with E2 and ROS modulators, Akt activations were significantly reduced
(Figs.6B&C). This data indicates that E2 induced PTEN inactivation and activation of
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Akt signaling cascade in breast cancer cells are redox dependent. Activated Akt can in
turn phosphorylate downstream substrates such as transcription factors that favor survival
and growth of breast cancer cells.

Estrogen induces NRF1 expression and phosphorylation in MCF7 cells. To
determine the effect of Estrogen induced PTEN oxidation on downstream Akt signaling
substrates, Immunohistochemistry assays were carried out to determine how E2 induced
ROS affect NRF1 expression and phosphorylation. Results show an increase in NRF1
expression and phosphorylation in E2 treated cells compared to DMSO control (Fig.7).

Estrogen induced ROS mediates NFR-1 binding to promoter regions of cell cycle
genes in MCF7 cells. A chromatin immunoprecipitation assay was carried out to
determine the effect of E2 on NRF1 binding as described in methods. Result obtained
shows an E2 induced increase in NRF1 binding to the promoter region of the following
cell cycle genes: CyclinB1, CDC2, PCNA, CDC25C and PRC1 (Fig. 8, Panels I &IIA).
Conversely, Antioxidant pre-treatment significantly inhibited the E2 induced NRF1
binding to the promoter region of the same genes (Fig. 8, Panels I &IIB).

Estrogen induced ROS mediates transcription of Cell cycle genes. RT-PCR was
carried out to determine the effect of E2 induced ROS on the transcription of cell cycle
genes as shown in methods. Result obtained show an up-regulation in the transcription of
CyclinB1, PCNA, CDC25C and PRC1 (Fig.9, Panels I&IIA). However, when cells were
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co-treated with either CAT or Eb, there was a significant inhibition of E2 induced
transcription upregulation of the same genes (Fig.9, Panels I&IIB).

Discussion
The results of our study show that estrogen-induced reactive oxidants have the capacity
to stimulate cell proliferation in MCF7 breast cancer cells through the oxidation of
PTEN, and the post translational modification of its downstream target.

In line with previous work done

23

, we are able to show here that estrogen-induced

reactive oxygen species (ROS) is capable of promoting DNA synthesis and cell
proliferation, which can be inhibited by exposure of the same cells to either biological or
chemical antioxidants, Catalase or Ebselen (See figs. 1, 2 and 3).

In this study, we have been able to show for the first time in MCF7 cells that estrogeninduced ROS oxidizes PTEN within 30 minutes of exposure. In addition, we reveal herein the ability of either Catalase or Ebselen to reverse the oxidizing effect of estrogeninduced ROS. See figs.4 and 5. We also show here that estrogen-induced PTEN
inactivation in MCF7 cells results in an increase in the phosphorylation of one of its
downstream target kinases, Akt. This is in line with previous studies which showed an
increase in Akt phosphorylation following PTEN inactivation by agents other than
estrogen 13, 24, 25. Moreover, we have also been able show that the pre-exposure of MCF7
cells to either Catalase or Ebselen significantly reverses the E2-induced effect. See fig.6.
Also demonstrated in this study is a corresponding increase in both the expression and

128

phosphorylation of NRF1, which is a known Akt substrate that has been implicated in
cell growth and proliferation 18-20. (See figure 7).

Based on the work done by Cam et al.

18

, which showed NRF1 could collaborate with

E2F family members to regulate the expression of genes that are involved in cellular
proliferation, we explored the possibility of phosphorylated (active) NRF1 binding to the
promoter region of cell cycle genes. Evident in our study for the first time in MCF7 cells,
is an increase in the binding of Akt phosphorylated NRF1 to the promoter region of the
following cell cycle genes: CyclinB1; CDC25A; CDC2; PCNA and PRC1. It is also
worthy of mention that this promoter binding was significantly inhibited by the preexposure of MCF7 cells to either Catalase or manganese superoxide dismutase
(MnSOD). See fig. 8. We were further able to reveal a consequent increase, in the
transcription of these gene, which was also inhibited by pre-exposure to Catalase and
MnSOD (See fig. 9).

In summary we have been able to show for the first time in MCF7 cells, that estrogeninduced ROS inactivates PTEN with an ensuing increase in Akt phosphorylation. This
Increase in Akt phosphorylation results in an increase in NRF1 expression and
phosphorylation leading to the activation and binding of NRF1 to the promoter region of
some cell cycle genes, namely CyclinB1, CDC25A, CDC2, PCNA and PRC1 leading to
cell proliferation. We also show a corresponding increase in the transcription of these
genes. Additionally, we show for the first time that that pre-exposure of MCF7 cells to
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either biological or chemical antioxidants significantly inhibited the effect of estrogeninduced ROS on PTEN and its downstream substrates (See fig. 10).
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Figures and Legend
Fig 1-MCF7

Antioxidants inhibit E2 induced ROS in MCF7 cells. 1 x104cells/well were seeded in a
96-well plate overnight and serum starved for 24 hrs. Post-starvation 100uL/well of
HBSS containing 10uM DCFH-DA pre-diluted with Pluronic F-127 was added to each
well and incubated at 37oC for 20mins. DCFH-DA solution was then aspirated and
replaced with 100ul of HBSS containing the desired treatments. Cells were further
incubated for 5mins and fluorescence readings were taken using 485 nm and 535 nm as
excitation and emission filters, at intervals of 5mins. A) MCF7 cells treated with E2. B)
MCF7 cells over expressing Catalase (CAT) or pre-treated with Ebselen were exposed to
either E2 or DMSO. Assay was performed 3x and data is expressed as mean percentage
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change from control +/- SE, (p 0.05).

(*) denotes significance when treatment is

compared to DMSO control.

Fig 2-MCF7

Antioxidants inhibit DNA synthesis in MCF7 cells. 2.5 x 103 cells/well were seeded in
a 96-well plate overnight and exposed to chemical or biological antioxidants as described
in methods. After exposure to antioxidants, cells were then stimulated with E2 for 22 hrs
and pulsed labeled with BrdU for 2 hrs. BrdU assay was then carried out as
recommended by manufacturer. Colorimetric changes were acquired at 370 nm with a
Tecan Genios microplate reader at 5 mins interval. A) MCF7 cells treated with either E2
or DMSO B) MCF7 cells over expressing Catalase (CAT) or pre-treated with Ebselen
were treated with either E2 or DMSO. Assay was performed 3x and data is expressed as
mean percentage change from control +/- SE, (p 0.05). (*) denotes significance when
treatment is compared to DMSO control.
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Fig 3-MCF7

Antioxidants inhibit E2-induced anchorage independent growth in MCF7 cells.
Cells were incubated on soft agar with or without antioxidants exposure for 21 days and
colonies ≥60 microns in diameter were enumerated. A) Anchorage independent growth of
MCF7 cells exposed to either DMSO or E2 B) MCF7 cells pretreated with chemical
antioxidant. Assay performed 3x and data is expressed as mean percentage change from
control.
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Fig 4-MCF7

Hydrogen Peroxide (H2O2) oxidizes PTEN in a dose dependent manner in MCF7
cells. MCF7 cells were seeded and stimulated with different doses of H2O2 for 30min and
then harvested. Cellular protein extracts were then alkylated with NEM and subjected to
non-reducing SDS-PAGE followed by immunoblot analysis with antibodies to PTEN.
Assay was performed 3x and data is expressed as mean percentage change from control.
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Fig 5-MCF7

Antioxidants inhibit the E2-induced PTEN oxidation in MCF7 cells. Cells were pretreated with Ebselen for 3hrs and stimulated with either DMSO or E2 for 30mins.
Cellular protein extracts were then alkylated with NEM and subjected to nonreducing
SDS-PAGE followed by immunoblot analysis with antibodies to PTEN. A) MCF7 cells
treated with either E2 or DMSO. B) MCF7 cells over-expressing Catalase (CAT) or
Empty Vector (EV) treated with DMSO or E2. C) MCF7 cells pre-treated with Ebselen
were treated with either DMSO or E2. Assay was performed 3x and data is expressed as
mean percentage change from control +/- SE, (p 0.05). (*) denotes significance when
treatment is compared to DMSO control while (**) denotes significance when treatment
is compared EV control.
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Fig 6-MCF7

E2-induced PTEN oxidation activates Akt phosphorylation in MCF7 cells. Akt and
phospho-Akt levels were determined post PTEN oxidation by immunoblotting using
MCF7 cells pre-exposed with either biological (CAT) or chemical (Ebselen) antioxidants
and then treated with E2 for 30min to induce PTEN oxidation. A) MCF7 cells treated
with either E2 or DMSO B) MCF7 cells over-expressing Catalase (CAT) or Empty
Vector (EV) treated with DMSO or E2. C) MCF7 cells pre-treated with Ebselen were
treated with either DMSO or E2. Assay was performed 3x and data is expressed as mean
percentage change from control +/- SE, (p 0.05). (*) denotes significance when treatment
is compared to DMSO control while (**) denotes significance when treatment is
compared EV control.
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Fig7-MCF7.

E2 induces NRF1 expression and phosphorylation in MCF7 cells. 1.0 x104
cells/chamber were treated for 45mins with E2. Cells were then fixed with ice cold
methanol for 15mins, and permeabilized with 0.5% Triton X-100 for 30mins after which
they were blocked with 1% normal goat serum for 1hr and then probed simultaneously
with antibodies for NRF1 (red) phosphoserine (blue).The merged phosphorylated NRF1
is in pink.
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Fig 8-MCF7

E2-induced ROS mediates NFR-1 binding to the promoter region of cell cycle genes.
MCF7 cells were seeded, serum starved for 24 hrs and either infected with Adenovirus
over- expressing MnSOD (SOD) or Catalase (CAT) at m.o.i of 200pfu as shown in the
methods section. Cells were then exposed to either DMSO or E2 for 16hrs and harvested
for ChIP assay as described in methods. PCR were run on ABI Biosystem 7300
thermocycler with the following cycle conditions: 95 ºC, 10 min; 40 cycles of (95 ºC, 15
sec; 60 ºC, 60 sec). PANEL I: PCR were run with primers for PRC1 and CDC2. A)
MCF7 cells were treated with either E2 or DMSO B) MCF7cells over expressing CAT or
SOD were treated with either DMSO or E2. Assay was performed 3x and data is
expressed as mean percentage change from control. PANELII: PCR were run with
primers for PCNA, CyclinB1 and CDC25C. A) MCF7 cells were treated with either E2
or DMSO B) MCF7 cells over expressing CAT or SOD were treated with either DMSO
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or E2. Assays was performed 3x and data is expressed as mean percentage change from
control.

Fig 9-MCF7

E2-induced ROS mediates transcription of cell cycle genes. MCF7 cells were seeded,
serum starved for 24 hrs and either infected with Adenovirus over- expressing MnSOD
(SOD) or Catalase (CAT) at m.o.i of 200pfu as shown in the methods section. Cells were
then exposed to either DMSO or E2 for 24hrs and harvested for RT-PCR as described in
methods. RT- PCR were run on ABI Biosystem 7300 thermocycler with the following
cycle conditions: initial initiation Step set at 48oC for 30mins; and 95 oC for 10min (1
cycle) and the PCR step at 95oC for 15sec and 60sec for 1min (40 cycle). PANEL I: RTPCR were run with primers for CyclinB1. A) MCF7 cells were treated with either E2 or
DMSO B) MCF7cells over expressing CAT or SOD were treated with either DMSO or
E2. Assay was performed 3x and data is expressed as mean percentage change from
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control. PANELII: RT-PCR was run with primers for PCNA, PRC1 and CDC25C. A)
MCF7 cells were treated with either E2 or DMSO B) MCF7cells over expressing CAT or
SOD were treated with either DMSO or E2. Assays was performed 3x and data is
expressed as mean percentage change from control.

Fig 10-MCF7

A schematic showing our hypothesized pathway. Estrogen-induced ROS inactivates
PTEN with an ensuing increase in Akt phosphorylation. This Increase in Akt
phosphorylation results in an increase in NRF1 expression and phosphorylation leading
to the activation and binding of NRF1 to the promoter region of some cell cycle genes.

V CONCLUSION
The goal of this dissertation was to investigate and hopefully reveal the role of ROS in
the conversion of tamoxifen sensitive breast tumors to a tamoxifen-resistant phenotype.

141

Our research was based on the working hypothesis that excess ROS oxidizes protein
tyrosine phosphatases (PTPs), thereby changing the phosphorylation state and altering the
functions of certain key signaling proteins such as p27 (a Cyclin dependent kinase
inhibitor) and nuclear respiratory factor 1(NRF-1) (a transcription factor).We further
postulated that if ROS/redox signaling has a role in the development of tamoxifen
resistance, then we may be able to restore sensitivity to tamoxifen by pre-exposing
resistant breast cancer cells to antioxidants.

In the course of our research, using tamoxifen resistant LCC2 breast cancer cells, we
found tamoxifen to be highly pro-oxidant, based on its ability to induce ROS formation
when it is used to stimulate LCC2 cells. We further discovered that tamoxifen acts as an
ROS scavenger (antioxidant) in the presence of estrogen. Upon further investigation we
found that stimulating LCC2 cells with tamoxifen resulted in a reduction in the
expression of p27 protein and an increase in its phosphorylation on threoning 157 and
187 respectively which correlated with an increase in cell proliferation. Interestingly, we
were able to reverse these findings using biological (MnSOD and Catalase) and chemical
(Ebselen) antioxidants. Meaning that LCC2cells which were pre-exposed to antioxidants
showed a significant increase in p27 expression and a reduction in the phosphorylation of
p27 implying a possible growth inhibitory effect.

Our findings then raised a question about what aspect of p27 was really affected in the
development of tamoxifen resistance. Was it a decrease in p27 expression or just the
inability of the protein to carry out its growth inhibitory function? So we compared the
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level of p27 in tamoxifen sensitive MCF7 breast cancer cells to that in tamoxifen resistant
breast cancer cells and found that the level of p27 in LCC2 cells was significantly less
than in MCF7 demonstrating that if tamoxifen resistance is as a result of a reduction in
p27 expression, then our finding that pre-exposure to anti-oxidants t increases p27
expression was a significant one. We then conducted a p27 stability assay comparing
cells pre- exposed to anti-oxidant to those which were not. Again we found that those
cells pre-exposed to anti-oxidants showed more p27 stability compared to those which
were not. We also conducted a functional assay to determine the effect of our findings on
the function of p27, again we found that cells which were pre-exposed to anti-oxidants
were more functional because they exhibited more binding capacity of p27 to CyclinE
and Cdk2 compared to cells which were not exposed to anti-oxidants. As mentioned
previously in this dissertation, the growth inhibitory effect of p27 is based on its ability to
bind to the CylinE-Cdk2 complex.

Putting all our findings together we may therefore infer that, the development of
tamoxifen resistance is due to the ability of tamoxifen to produce a sustained increase in
ROS which results in a pro-oxidative environment. In a pro-oxidative environment the
expression and stability of p27 is diminished resulting in loss of its inhibitory function
because there is not enough p27 to bind and inhibit the growth promoting CyclinE-CDK2
complex. Therefore our findings that anti-oxidants increased p27 expression, stability and
binding are very significant.
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To determine the mechanism of tamoxifen resistance, we used Tamoxifen sensitive
MCF7 cells to determine the effect of ROS on the loss of tamoxifen sensitivity and
demonstrated that in a pro-oxidant environment, the sustained increase in ROS level
leads to the oxidation and inhibition of the phosphatase PTEN with a consequent increase
in the phosphorylation of Akt. An increase in Akt phosphorylation then results in the
phosphorylation and activation of NRF-1. We then demonstrated that activated NRF-1
then binds to the promoter region of the following cell cycle genes: PCNA, cyclinB1,
CDC25A and PRC1 leading to their transcription and culminating in a sustained cell
proliferation. This finding could also be used to explain what happens in the case of p27
because Akt has been shown to phosphorylate p27 on T157 resulting in the cytoplasmic
sequestration of p27 and loss of its inhibitory function.

In a nutshell, we have been able to experimentally demonstrate that ROS/redox signaling
contributes to the evolution of breast cancer from a tamoxifen sensitive to a tamoxifen
resistant phenotype. The Findings of this study will elucidate the roles of the cellular
redox state, redox signaling pathways, PTPs and p27 in anti-estrogen resistance, and may
lead to new therapeutic strategies to delay or even prevent this important clinical
problem. This is a new line of research that may lay the groundwork for clinical trials of
anti-estrogens plus antioxidant-based drugs for the prevention and treatment of estrogendependent breast
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Directions for future research
As mentioned in the conclusion part of this dissertation, using MCF 7 cells we could also
demonstrate the effect of Akt phosphorylation on T157 and subsequently p27 function.
We have conducted preliminary studies in our lab and the results are encouraging.

Since our current research was done in vitro, another area for further research would be a
test of our hypothesis in vivo. Xenografted tumors in nude mice will be used to determine
if ROS inhibitors or glutathione or thioredoxin modifiers can cooperate with antiestrogens to inhibit the proliferation of anti-estrogen-resistant breast cancer cells.
Findings of this study will reveal the roles of the cellular redox state, redox signaling
pathways and p27/NRF-1 in anti-estrogen resistance, and may lead to new therapeutic
strategies to delay or even to prevent this important clinical problem. This is a new line of
research that may lay the groundwork for clinical trials of anti-estrogens plus antioxidantbased drugs for the prevention and treatment of estrogen-dependent breast cancer.
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